{"id":3422,"date":"2016-04-03T21:25:29","date_gmt":"2016-04-03T18:25:29","guid":{"rendered":"http:\/\/sahibimben.com\/?p=3422"},"modified":"2020-03-18T23:21:53","modified_gmt":"2020-03-18T20:21:53","slug":"ozur-durumuna-gore-ozurluluk-engellilik-orani-cetveli","status":"publish","type":"post","link":"https:\/\/www.stil-vagonu.com\/kadin\/ozur-durumuna-gore-ozurluluk-engellilik-orani-cetveli\/","title":{"rendered":"\u00d6z\u00fcr Durumuna G\u00f6re \u00d6z\u00fcrl\u00fcl\u00fck Engellilik Oran\u0131 Cetveli"},"content":{"rendered":"

Sevgili okuyucular\u0131m\u0131z. Sizlere erken emekli olmak i\u00e7in \u00f6z\u00fcrl\u00fc oran\u0131 hesaplama<\/em>, erken emeklilik i\u00e7in engllilik oran\u0131\u00a0 hesab\u0131<\/strong>, erken emekli olmak i\u00e7in<\/strong> \u00d6z\u00fcrl\u00fcl\u00fck Engellilik Oran\u0131 Cetveli<\/strong>ni sunuyorum.\u00a0 Nedeni \u0130se; Bir arkada\u015f\u0131m erken emekli olmak\u00a0 i\u00e7in hastal\u0131\u011f\u0131n\u0131n engellilik \u00f6z\u00fcrl\u00fcl\u00fck oran\u0131n\u0131n % ka\u00e7 oldu\u011funu merak ettik. Ara\u015ft\u0131rd\u0131k do\u011fru d\u00fcr\u00fcst bir bilgi bulamad\u0131k.<\/p>\n

Resimde \u00c7al\u0131\u015fma g\u00fcc\u00fc kay\u0131p oranlar\u0131<\/strong> verilmi\u015ftir.<\/p>\n

Bildi\u011finiz gibi Engellilik \u00c7al\u0131\u015fma G\u00fcc\u00fc Kayb\u0131 Oran\u0131<\/strong> erken\u00a0 emeklili\u011fe esas kabul edilir.<\/p>\n

A\u015fa\u011f\u0131daki resimde \u00f6z\u00fcrl\u00fcl\u00fck raporunun derecesi verilmi\u015ftir.<\/p>\n

\u00c7al\u0131\u015fma G\u00fcc\u00fc Kayb\u0131 Oran\u0131<\/strong> Cetvelimizi bulabileceksiniz.<\/p>\n

Biz de sizler i\u00e7in B\u00fct\u00fcn Hastal\u0131klar\u0131n \u00d6z\u00fcrl\u00fcl\u00fck Engellilik Oran\u0131<\/strong>n\u0131 belirten bir word dosyas\u0131n\u0131 payla\u015fmaya karar verdik.<\/p>\n

Bu dosyada hangi \u00f6zr\u00fcn ka\u00e7 puan oldu\u011fu belirtiliyor. B\u00f6ylece emeklili\u011fe esas \u00f6z\u00fcr oran\u0131<\/strong>n\u0131 hesaplayabileceksiniz.<\/p>\n

\u00d6z\u00fcr oranlar\u0131 cetveli 2016<\/strong> yaz\u0131m\u0131zda a\u015fa\u011f\u0131da verdi\u011fimiz ek dosyay\u0131 dikkatle inceleyiniz.<\/p>\n

Bu linkten<\/p>\n

\u00d6z\u00fcr Durumuna G\u00f6re \u00c7al\u0131\u015fma G\u00fcc\u00fc Kayb\u0131, Engellilik, \u00d6z\u00fcrl\u00fc Raporlar\u0131 Oranlar\u0131 Cetveli<\/a><\/strong><\/p>\n

indirebilirsiniz.<\/p>\n

Veya a\u015fa\u011f\u0131dan hastal\u0131\u011f\u0131n\u0131z\u0131 ve engellilik oran\u0131n\u0131 bulabilirsiniz.<\/p>\n

\u00d6z\u00fcr Durumuna G\u00f6re \u00c7al\u0131\u015fma G\u00fcc\u00fc Kayb\u0131 Oranlar\u0131 Cetveli: <\/strong><\/p>\n

\u00a0<\/strong><\/p>\n

\u00a0<\/strong>1- N\u00d6ROLOJ\u0130K HASTALIKLAR<\/strong>\u00a0\u00a0\u00a0\u00a0 \u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

PAREZ\u0130LER<\/strong>
\nMonoparezi \u00dcst Ekstremite
\nHafif 15
\nOrta 20
\nPleji 55<\/p>\n

Monoparezi Alt Eksremite
\nHafif 15
\nOrta 20
\nPleji 50<\/p>\n

Hemiparezi
\nHafif 35
\nOrta 40
\nHemipleji 80<\/p>\n

Paraparezi veya Diparezi
\nHafif 35
\nOrta 45
\nParapleji veya dipleji 80
\nParapleji + \u0130ncontinans 95
\nKuadriparezi 60
\nKuadropleji 100<\/p>\n

Afaziler Motor
\nHafif 10
\nOrta 25
\nA\u011f\u0131r 45<\/p>\n

Sensoriel
\nHafif 15
\nOrta 30
\nA\u011f\u0131r 50<\/p>\n

Mikst tip afazilerde a\u011f\u0131r olana g\u00f6re puanlama yap\u0131l\u0131r.<\/p>\n

Parkinson Hastal\u0131\u011f\u0131
\nHafif 30
\nOrta 45
\nA\u011f\u0131r (Y\u00fcr\u00fcyemeyen, ya\u015famsal aktiviteyi tamamen engelleyen) 90<\/p>\n

Distonik bozukluklar ve di\u011fer hareket bozukluklar\u0131
\nFonksiyon kaybeden ekstremiteye g\u00f6re parezi ile e\u015fde\u011fer puan verilir.<\/p>\n

Kas hastal\u0131klar\u0131
\nHafif (Hafif fonksiyon kayb\u0131) 40
\nOrta (Dstekle y\u00fcr\u00fcyebilen) 50
\nA\u011f\u0131r (Y\u00fcr\u00fcyemeyen) 90<\/p>\n

Multiple Skleroz
\nFonksiyon kayb\u0131 dikkate al\u0131narak parezi derecesine g\u00f6re
\npuanlama yap\u0131l\u0131r.<\/p>\n

EP\u0130LEPS\u0130
\nFokal n\u00f6betler Ayda 2 den az 20
\nAyda 2 den fazla 40<\/p>\n

Jeneralize motor hareketler
\nY\u0131lda 1 – 2 40
\nY\u0131lda 2 den fazla 65<\/p>\n

Petit mal epilepsi
\n– Ayda 2 den az 20
\n– Ayda 2 den fazla 40<\/p>\n

Serebellar bozukluklar
\n– Yaln\u0131zca Dismetri 10
\n– Ataksi
\nHafif 15
\nOrta 20
\nA\u011f\u0131r 40<\/p>\n

TREMOR
\nHer iki elde ve i\u015f g\u00f6rmeyi engellemeyen tremor 10
\nHer iki elde ve i\u015f g\u00f6rmeyi engelleyen tremor 40<\/p>\n

Polin\u00f6ropati
\nMotor defisit yapmayan 10
\nMotor defisit varsa Ekstremite parezi derecesi ile e\u015fde\u011fer
\npuan verilir.<\/p>\n

BA\u015e KEM\u0130KLER\u0130N\u0130N A\u00c7IKLIKLARI
\n9-25 cm2 (kapat\u0131lmam\u0131\u015fsa) 10
\n9-25 cm2 (kapat\u0131lm\u0131\u015fsa) 5
\n25 cm2 den geni\u015f (kapat\u0131lmam\u0131\u015fsa) 20
\n25 cm2 den geni\u015f (kapat\u0131lm\u0131\u015fsa) 15<\/p>\n

Cerebral Palsi fonksiyon kay\u0131plar\u0131na g\u00f6re de\u011ferlendirilir<\/p>\n

\u00a0<\/strong><\/p>\n

2- RUH HASTALIKLARI\u00a0\u00a0\u00a0\u00a0 <\/strong>\u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

\u00a0<\/strong><\/p>\n

1-S\u00fcrekli i\u015f g\u00fcc\u00fc kayb\u0131na neden olan ruhsal hastal\u0131klar<\/p>\n

A- Zeka Gerili\u011fi<\/p>\n

a- Hafif (IQ 50-69)\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

b- Orta (IQ 35-49)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 60<\/p>\n

c- A\u011f\u0131r (IQ 20-34)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

d- \u00c7ok a\u011f\u0131r (IQ 20\u2019nin alt\u0131nda)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 100<\/p>\n

B- Demans \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

C- \u015eizofreni (Paranoid, hebefrenik, katatonik, ayr\u0131\u015fmam\u0131\u015f, basit tip \u015fizofreni ile<\/p>\n

post-\u015fizofrenik depresyon ve kal\u0131nt\u0131l\u0131 depresyonu i\u00e7erir)<\/p>\n

a- Tedaviyle \u00e7al\u0131\u015fma olana\u011f\u0131 veren\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 45<\/p>\n

b- Tedaviyle \u00e7al\u0131\u015fma olana\u011f\u0131 vermeyen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

D- \u015eizoaffektif bozukluk (manik, depresif ve kar\u0131\u015f\u0131k tip)<\/p>\n

a- Tedaviyle \u00e7al\u0131\u015fma olana\u011f\u0131 veren\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 45<\/p>\n

b- Tedaviyle \u00e7al\u0131\u015fma olana\u011f\u0131 vermeyen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

E- Sanr\u0131sal bozukluklar (paranoya, paranoid psikoz, parafreni tan\u0131lar\u0131n\u0131 i\u00e7erir)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a060<\/p>\n

F- Psikoaktif madde kullan\u0131m\u0131na ba\u011fl\u0131 bozukluklar<\/p>\n

a- Psikotik bozukluk (alkol hal\u00fcsinozisi, alkol paranoyas\u0131n\u0131 i\u00e7erir)\u00a0\u00a0\u00a0\u00a0 60<\/p>\n

b- Amnezik sendrom ( Korsakof psikozu ve alkol demans\u0131n\u0131 i\u00e7erir)\u00a0\u00a0 80<\/p>\n

G- Otizm\u00a0\u00a0 70<\/p>\n

II- Ge\u00e7ici i\u015f g\u00fcc\u00fc kayb\u0131na neden olan ruhsal hastal\u0131klar :<\/p>\n

( Bu gruptaki hastal\u0131klar 1 y\u0131l sonra kontrol gerektirir.)<\/p>\n

A- Beyin hasar\u0131, beyin i\u015flev bozuklu\u011fu ve bedensel hastal\u0131klara ba\u011fl\u0131<\/p>\n

Ruhsal bozukluklar<\/p>\n

Organik hallusinozis<\/p>\n

Organik duygulan\u0131m bozuklu\u011fu<\/p>\n

Organik sanr\u0131l\u0131 bozukluk<\/p>\n

Organik bunalt\u0131 bozuklu\u011fu<\/p>\n

a- Tedavi edilebilen\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

b- Tedavi edilemeyen\u00a0\u00a0 60<\/p>\n

B- Beyin hasar\u0131, beyin i\u015flev bozuklu\u011funa ba\u011fl\u0131 davran\u0131\u015f bozukluklar\u0131<\/p>\n

Organik ki\u015filik bozuklu\u011fu (Frontal lob sendromunu i\u00e7erir)<\/p>\n

Beyin sars\u0131lmas\u0131 sonras\u0131 (postcontussional) sendromu<\/p>\n

a- Tedavi edilebilen\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

b- Tedavi edilemeyen\u00a0\u00a0 60<\/p>\n

C- Duygudurum bozukluklar\u0131<\/p>\n

Manik n\u00f6bet<\/p>\n

Bipolar duygulan\u0131m bozuklu\u011fu<\/p>\n

Yineleyici depresif bozukluk<\/p>\n

\u0130nat\u00e7\u0131 duygudurum bozuklu\u011fu<\/p>\n

Siklotimi<\/p>\n

Distimi<\/p>\n

a- Tedaviyle \u00e7al\u0131\u015fma olana\u011f\u0131 veren\u00a0\u00a0\u00a0 40<\/p>\n

b- Tedavi edilemeyen 65<\/p>\n

D- Nevrotik, stresle ilgili ve somatoform bozukluklar<\/p>\n

fobik bunalt\u0131 bozuklu\u011fu<\/p>\n

obsesif kompulsif bozukluk<\/p>\n

panik bozuklu\u011fu<\/p>\n

dissosiyatif bozukluk (konversiyon bozuklu\u011fu)<\/p>\n

a\u011f\u0131r stres tepkisi ve uyum bozuklu\u011fu<\/p>\n

Nevrasteni<\/p>\n

depersonalizasyon-derealizasyon sendromu<\/p>\n

a- Tedavi edilebilen\u00a0\u00a0\u00a0 25<\/p>\n

b- Tedavi edilemeyen 60<\/p>\n

E- Psikoaktif madde kullan\u0131m\u0131na ba\u011fl\u0131 ruhsal ve davran\u0131\u015fsal bozukluklar<\/p>\n

Duygulan\u0131m bozuklu\u011fu<\/p>\n

Ba\u011f\u0131ml\u0131l\u0131k sendromu<\/p>\n

a- Tedavi edilebilen\u00a0\u00a0\u00a0 25<\/p>\n

b- Tedavi edilemeyen 60<\/p>\n

(i\u015fe girmelerde ve vergi indiriminde bu derecelendirme dikkate al\u0131nmaz)<\/p>\n

F- Ki\u015filik bozukluklar\u0131\u00a0\u00a0\u00a0 30<\/p>\n

Paranoid ki\u015filik bozuklu\u011fu<\/p>\n

\u015eizoid ki\u015filik bozuklu\u011fu<\/p>\n

Antisosyal ki\u015filik bozuklu\u011fu<\/p>\n

Duygusal y\u00f6nden dengesiz ki\u015filik bozuklu\u011fu (s\u0131n\u0131r ki\u015filik bozuklu\u011funu da i\u00e7erir)<\/p>\n

Histriyonik ki\u015filik bozuklu\u011fu<\/p>\n

Anankastik ki\u015filik bozuklu\u011fu<\/p>\n

Ka\u00e7\u0131nan ki\u015filik bozuklu\u011fu<\/p>\n

Ba\u011f\u0131ml\u0131 ki\u015filik bozuklu\u011fu<\/p>\n

G- Cinsel kimlik bozukluklar\u0131<\/p>\n

Cinsel se\u00e7im bozukluklar\u0131<\/p>\n

(Transeks\u00fcalizm, feti\u015fizm, g\u00f6sterimcilik, \u00e7ocu\u011fa cinsel sevi,<\/p>\n

sadomazoizmi i\u00e7erir)<\/p>\n

a- Tedavi edilebilen\u00a0\u00a0\u00a0 15<\/p>\n

b- Tedavi edilemeyen 60<\/p>\n

(i\u015fe girmelerde ve vergi indiriminde bu derecelendirme dikkate al\u0131nmaz)<\/p>\n

Ge\u00e7ici i\u015f g\u00fcc\u00fc kayb\u0131na neden olan ruhsal hastal\u0131klar bir y\u0131l sonra<\/p>\n

de\u011ferlendirilip kesin karara var\u0131lacakt\u0131r.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
\n<\/strong><\/p>\n

3- G\u00d6Z ARIZALARI<\/strong> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %
\n1-) G\u00f6rme Bozukluklar\u0131
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0 g\u00f6rmesi 32
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0.1 g\u00f6rmesi 30
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0.2 g\u00f6rmesi 25
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0.3 g\u00f6rmesi 20
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0.4 g\u00f6rmesi 15
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0.5 g\u00f6rmesi 10
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0.6 g\u00f6rmesi 4
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0.7 g\u00f6rmesi 3
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0.8 g\u00f6rmesi 2
\nBir g\u00f6z\u00fcn 1.0, di\u011ferinin 0.9 g\u00f6rmesi 1<\/p>\n

Bir g\u00f6z\u00fcn 0.9, di\u011ferinin 0 g\u00f6rmesi 35
\nBir g\u00f6z\u00fcn 0.9, di\u011ferinin 0.1 g\u00f6rmesi 30
\nBir g\u00f6z\u00fcn 0.9, di\u011ferinin 0.2 g\u00f6rmesi 25
\nBir g\u00f6z\u00fcn 0.9, di\u011ferinin 0.3 g\u00f6rmesi 20
\nBir g\u00f6z\u00fcn 0.9, di\u011ferinin 0.4 g\u00f6rmesi 15
\nBir g\u00f6z\u00fcn 0.9, di\u011ferinin 0.5 g\u00f6rmesi 10
\nBir g\u00f6z\u00fcn 0.9, di\u011ferinin 0.6 g\u00f6rmesi 5
\nBir g\u00f6z\u00fcn 0.9, di\u011ferinin 0.7 g\u00f6rmesi 4
\nBir g\u00f6z\u00fcn 0.9, di\u011ferinin 0.8 g\u00f6rmesi 3
\nBir g\u00f6z\u00fcn 0.9, di\u011ferinin 0.9 g\u00f6rmesi 2<\/p>\n

Bir g\u00f6z\u00fcn 0.8, di\u011ferinin 0 g\u00f6rmesi 40
\nBir g\u00f6z\u00fcn 0.8, di\u011ferinin 0.1 g\u00f6rmesi 35
\nBir g\u00f6z\u00fcn 0.8, di\u011ferinin 0.2 g\u00f6rmesi 30
\nBir g\u00f6z\u00fcn 0.8, di\u011ferinin 0.3 g\u00f6rmesi 25
\nBir g\u00f6z\u00fcn 0.8, di\u011ferinin 0.4 g\u00f6rmesi 20
\nBir g\u00f6z\u00fcn 0.8, di\u011ferinin 0.5 g\u00f6rmesi 15
\nBir g\u00f6z\u00fcn 0.8, di\u011ferinin 0.6 g\u00f6rmesi 10
\nBir g\u00f6z\u00fcn 0.8, di\u011ferinin 0.7 g\u00f6rmesi 5
\nBir g\u00f6z\u00fcn 0.8, di\u011ferinin 0.8 g\u00f6rmesi 4
\nBir g\u00f6z\u00fcn 0.8, di\u011ferinin 0.9 g\u00f6rmesi 3<\/p>\n

Bir g\u00f6z\u00fcn 0.7, di\u011ferinin 0 g\u00f6rmesi 45
\nBir g\u00f6z\u00fcn 0.7, di\u011ferinin 0.1 g\u00f6rmesi 40
\nBir g\u00f6z\u00fcn 0.7, di\u011ferinin 0.2 g\u00f6rmesi 35
\nBir g\u00f6z\u00fcn 0.7, di\u011ferinin 0.3 g\u00f6rmesi 30
\nBir g\u00f6z\u00fcn 0.7, di\u011ferinin 0.4 g\u00f6rmesi 25
\nBir g\u00f6z\u00fcn 0.7, di\u011ferinin 0.5 g\u00f6rmesi 20
\nBir g\u00f6z\u00fcn 0.7, di\u011ferinin 0.6 g\u00f6rmesi 15
\nBir g\u00f6z\u00fcn 0.7, di\u011ferinin 0.7 g\u00f6rmesi 10<\/p>\n

Bir g\u00f6z\u00fcn 0.6,di\u011ferinin 0 g\u00f6rmesi 50
\nBir g\u00f6z\u00fcn 0.6,di\u011ferinin 0.1 g\u00f6rmesi 45
\nBir g\u00f6z\u00fcn 0.6,di\u011ferinin 0.2 g\u00f6rmesi 40
\nBir g\u00f6z\u00fcn 0.6,di\u011ferinin 0.3 g\u00f6rmesi 35
\nBir g\u00f6z\u00fcn 0.6,di\u011ferinin 0.4 g\u00f6rmesi 30
\nBir g\u00f6z\u00fcn 0.6,di\u011ferinin 0.5 g\u00f6rmesi 25
\nBir g\u00f6z\u00fcn 0.6,di\u011ferinin 0.6 g\u00f6rmesi 20<\/p>\n

Bir g\u00f6z\u00fcn 0.5,di\u011ferinin 0 g\u00f6rmesi 55
\nBir g\u00f6z\u00fcn 0.5,di\u011ferinin 0.1 g\u00f6rmesi 50
\nBir g\u00f6z\u00fcn 0.5,di\u011ferinin 0.2 g\u00f6rmesi 45
\nBir g\u00f6z\u00fcn 0.5,di\u011ferinin 0.3 g\u00f6rmesi 40
\nBir g\u00f6z\u00fcn 0.5,di\u011ferinin 0.4 g\u00f6rmesi 35
\nBir g\u00f6z\u00fcn 0.5,di\u011ferinin 0.5 g\u00f6rmesi 30<\/p>\n

Bir g\u00f6z\u00fcn 0.4,di\u011ferinin 0 g\u00f6rmesi 60
\nBir g\u00f6z\u00fcn 0.4,di\u011ferinin 0.1 g\u00f6rmesi 55
\nBir g\u00f6z\u00fcn 0.4,di\u011ferinin 0.2 g\u00f6rmesi 50
\nBir g\u00f6z\u00fcn 0.4,di\u011ferinin 0.3 g\u00f6rmesi 45
\nBir g\u00f6z\u00fcn 0.4,di\u011ferinin 0.4 g\u00f6rmesi 40<\/p>\n

Bir g\u00f6z\u00fcn 0.3,di\u011ferinin 0 g\u00f6rmesi 70
\nBir g\u00f6z\u00fcn 0.3,di\u011ferinin 0.1 g\u00f6rmesi 65
\nBir g\u00f6z\u00fcn 0.3,di\u011ferinin 0.2 g\u00f6rmesi 60
\nBir g\u00f6z\u00fcn 0.3,di\u011ferinin 0.3 g\u00f6rmesi 55<\/p>\n

Bir g\u00f6z\u00fcn 0.2,di\u011ferinin 0 g\u00f6rmesi 85
\nBir g\u00f6z\u00fcn 0.2,di\u011ferinin 0.1 g\u00f6rmesi 80
\nBir g\u00f6z\u00fcn 0.2,di\u011ferinin 0.2 g\u00f6rmesi 75<\/p>\n

Bir g\u00f6z\u00fcn 0.1,di\u011ferinin 0 g\u00f6rmesi 95
\nBir g\u00f6z\u00fcn 0.1,di\u011ferinin 0.1 g\u00f6rmesi 90
\nBir g\u00f6z\u00fcn 0 ,di\u011ferinin 0 g\u00f6rmesi 100
\n60 ya\u015f\u0131n \u00fczerindekilere Balthazard form\u00fcl\u00fc ile %10 eklenir.<\/p>\n

2-)\u00c7ift g\u00f6rmeye neden olan kal\u0131c\u0131 g\u00f6z kas\u0131 paralizisi 20
\n(Tek bir bak\u0131\u015f y\u00f6n\u00fcndeyse)<\/p>\n

3-)\u00c7ift g\u00f6rmeye neden olan kal\u0131c\u0131 g\u00f6z kas\u0131 paralizisi 40
\n(Birden fazla bak\u0131\u015f y\u00f6n\u00fcndeyse)<\/p>\n

4-)Lagoftalmi
\na-Tek g\u00f6zde 1\/2 ve fazlas\u0131 tarsorafi gerektiren 10
\nb-\u00c7ift g\u00f6zde 1\/2 ve fazlas\u0131 tarsorafi gerektiren 35<\/p>\n

5-)Entropion,Ektropion (sekel haldeki)
\na-Tek g\u00f6zde 5
\nb-\u00c7ift g\u00f6zde 10<\/p>\n

6-) Lakrimal kanal t\u0131kanmalar\u0131 ve travmalar\u0131 (sekel haldeki)
\na- Tek g\u00f6zde 5
\nb- \u00c7ift g\u00f6zde 10<\/p>\n

7-) Sekel halinde yar\u0131m ptozis
\na- Tek g\u00f6zde 5
\nb- \u00c7ift g\u00f6zde 15<\/p>\n

\ud83d\ude0e G\u00f6rme alan\u0131nda daralma (g\u00f6rme alan\u0131 40\u00b0)
\na- Preferik d\u00fczensiz daralma
\n– Tek g\u00f6zde 10
\n– \u00c7ift g\u00f6zde 15
\nb- G\u00f6rme alan\u0131 30\u00b0
\n– Tek g\u00f6zde 15
\n– \u00c7ift g\u00f6zde 45
\nc- G\u00f6rme alan\u0131 20\u00b0
\n– Tek g\u00f6zde 25
\n– \u00c7ift g\u00f6zde 60
\nd- Hemianopsiler 60<\/p>\n

9-) Bilateral afak nedeniyle binok\u00fcler g\u00f6rmesi olanlarda \u00e7al\u0131\u015fma
\ng\u00fcc\u00fc kayb\u0131 oran\u0131na Balthazard form\u00fcl\u00fc ile % 10, ps\u00f6dofaklarda %5
\neklenir. Anizometropi varsa \u00e7al\u0131\u015fma g\u00fcc\u00fc
\nkayb\u0131 oran\u0131na Balthazard form\u00fcl\u00fc ile % 2 eklenir..<\/p>\n

10-)Tek tarafl\u0131 afak olgular\u0131nda binok\u00fcler g\u00f6rme yoksa, \u00e7al\u0131\u015fma
\ng\u00fcc\u00fc kayb\u0131 oran\u0131na, Balthazard form\u00fcl\u00fc ile % 12 eklenir,
\nps\u00f6dofaklarda % 7 eklenir.<\/p>\n

11-)Retina dekolman ameliyatl\u0131 olgularda g\u00f6rme bozuklu\u011funa ba\u011fl\u0131 \u00e7al\u0131\u015fma
\ng\u00fcc\u00fc kayb\u0131, g\u00f6rme ve g\u00f6rme alan\u0131 kayb\u0131na g\u00f6re de\u011ferlendirilir. Eklemeler
\nBalthazard form\u00fcl\u00fc ile yap\u0131l\u0131r.<\/p>\n

12-)Glokomda g\u00f6rme bozuklu\u011funa ba\u011fl\u0131 \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131, g\u00f6rme ve
\ng\u00f6rme alan\u0131 kayb\u0131na g\u00f6re de\u011ferlendirilir. Eklemeler Balthazard form\u00fcl\u00fc
\nile yap\u0131l\u0131r.<\/p>\n

13-)\u015ea\u015f\u0131l\u0131kta g\u00f6rme bozuklu\u011funa ba\u011fl\u0131 \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131na binok\u00fcler
\ng\u00f6rme varsa Balthazard form\u00fcl\u00fc ile % 10 eklenir.<\/p>\n

14-)\u015ea\u015f\u0131l\u0131kta g\u00f6rme bozuklu\u011funa ba\u011fl\u0131 \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131na binokuler
\ng\u00f6rme yoksa Balthazard form\u00fcl\u00fc ile % 15 eklenir.<\/p>\n

15-)Optik sinir hastal\u0131klar\u0131nda g\u00f6rme bozuklu\u011funa ba\u011fl\u0131 \u00e7al\u0131\u015fma
\ng\u00fcc\u00fc kayb\u0131 oran\u0131na Balthazard form\u00fcl\u00fc ile g\u00f6rme alan\u0131 kayb\u0131 eklenir.<\/p>\n

16-)Edinsel kataraktlar\u0131n g\u00f6rme fonksiyonunu kazanmas\u0131na engel ilave patoloji
\nyoksa, operasyon sonras\u0131 g\u00f6rme derecesi miktar\u0131na g\u00f6re de\u011ferlendirilir.<\/p>\n

4-<\/strong> KULAK, BURUN, BO\u011eAZ ARIZALARI<\/strong> \u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %
\nI- Kulak araz\u0131lar\u0131<\/p>\n

1- Do\u011fu\u015ftan (Konjenital) tam i\u015fitme ve konu\u015fma \u00f6z\u00fcrl\u00fcs\u00fc 55
\n2- Her iki kulakta tedavi ve i\u015fitme cihaz\u0131 ile giderilemeyen
\ntam i\u015fitme kayb\u0131 50
\n3- Denge bozukluklar\u0131 ile birlikte olan iki tarafl\u0131 i\u015fitme
\nkayb\u0131 55<\/p>\n

\u0130\u015fitme kayb\u0131n\u0131n ar\u0131za a\u011f\u0131rl\u0131k \u00f6l\u00e7\u00fcs\u00fc \u015fu \u015fekilde hesaplan\u0131r;
\nHer iki kulaktaki hava yolu i\u015fitme kayb\u0131n\u0131n odyometrik
\nortalamas\u0131 bulunur.
\nBu say\u0131 ki\u015finin tam sa\u011f\u0131rl\u0131k halinde u\u011frayaca\u011f\u0131 ar\u0131za a\u011f\u0131rl\u0131k
\n\u00f6l\u00e7\u00fcs\u00fc (%50) ile \u00e7arp\u0131l\u0131r.
\n\u00f6rnek
\n——
\nBir kulakta, i\u015fitme kayb\u0131 : 50 dB
\nDi\u011fer kulaktaki i\u015fitme kayb\u0131 : 80 dB
\nOrtalama : 80+50=130\/2=65
\nAr\u0131za a\u011f\u0131rl\u0131k \u00f6l\u00e7\u00fcs\u00fc : 65×0.5=%32,5
\nNot: 35 dB’den az i\u015fitme kay\u0131plar\u0131 de\u011ferlendirmeye al\u0131nmaz.<\/p>\n

II- Y\u00fcz Ar\u0131zalar\u0131
\n1- Burunda tam kay\u0131p 40
\n2- Burun ve sin\u00fcs bo\u015flu\u011funa a\u00e7\u0131lma ile birlikte maksillan\u0131n
\nparsiyel kayb\u0131 50
\n3- Fonksiyon kayb\u0131 ile birlikte alveoler \u00e7\u0131k\u0131nt\u0131da % 50’den
\nfazla damak kayb\u0131 (protezle d\u00fczeltilemeyecek) 40
\n4- Doku kayb\u0131, skarl\u0131 fiksasyon veya felce ba\u011fl\u0131 dilin
\nfonksiyon kayb\u0131:
\na- Hafif 30
\nb- A\u011f\u0131r 40
\n5- Kat\u0131 g\u0131da al\u0131m\u0131n\u0131 engelleyen \u00e7ene eklemi ankilozu 40
\n6- Gev\u015fek bir pseudoartrozla ile birlikte alt \u00e7enenin bir k\u0131sm\u0131n\u0131n
\nkayb\u0131:
\na- \u00c7i\u011fneme fonksiyonunda k\u0131s\u0131tlanma yoksa 20
\nb- \u00c7i\u011fneme fonksiyonu k\u0131s\u0131tlan\u0131yorsa 40
\n7- T\u00fckr\u00fck bezleri kanallar\u0131n\u0131n yaralanmas\u0131 veya hastal\u0131klar\u0131
\nsonucu s\u00fcrekli ve tedavi edilemeyen fist\u00fcl 7
\n8- Kal\u0131c\u0131 veya tekrarlayan,sekel mahiyette periferik fasyal
\nsinir paralizisi 10
\n9- Tam fonksiyon bozuklu\u011fu yapan dudak ar\u0131zalar\u0131 35<\/p>\n

III- Boyun Ar\u0131zalar\u0131
\n1- Larenks kayb\u0131
\na- K\u0131smi 30
\nb- Tam 70
\n2- Devaml\u0131 trakeostomi kan\u00fcl\u00fc kullan\u0131lmas\u0131 gereken durumlar 70
\n3- Ses organlar\u0131n\u0131n tedavi edilemeyen ar\u0131zalar\u0131
\na- Tek tarafl\u0131 (Disfoni) 10
\nb- \u0130ki tarafl\u0131 (afoni) 25
\nc- Dispne ile birlikte afoni 55<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0<\/strong><\/p>\n

5- KARIN HASTALIK VE ARIZALARI <\/strong>\u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

1- Ameliyat edilemeyen, ameliyatla d\u00fczeltilemeyen evantrasyonlar;<\/p>\n

    \n
  1. a) Hafif ( \u00e7ap\u0131 5 cm. ) 10<\/li>\n
  2. b) Orta ( \u00e7ap\u0131 10 cm.ye kadar ) 10<\/li>\n
  3. c) A\u011f\u0131r ( \u00e7ap\u0131 10 cm.den yukar\u0131 ) 20<\/li>\n<\/ol>\n

    2- Billroth II veya I Mide rezeksiyonu\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

    3- Total mide rezeksiyonu\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

    4- \u00d6zofagusun korozif darl\u0131klar\u0131, akalazya, kronik peptik \u00fclserler,<\/p>\n

    hiatus hernileri, postgastrektomik, postvagotomik sendromlar\u00a0\u00a0 20<\/p>\n

    5- Tedavi edilemeyen anal inkontinans\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 60<\/p>\n

    6- Daimi an\u00fcs kontrnaturalis\u00a0 80<\/p>\n

    7- 1 metreden az kalan barsak rezeksiyonlar\u0131\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 70<\/p>\n

    8- Hemikolektomi ( t\u00fcm\u00f6r d\u0131\u015f\u0131 nedenlerle )\u00a0 25<\/p>\n

    9- Totalkolektomi ( t\u00fcm\u00f6r d\u0131\u015f\u0131 nedenlerle )\u00a0\u00a0 50<\/p>\n

    10- Safra kesesi yoklu\u011fu\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5<\/p>\n

    11- Splenektomi ( kan hastal\u0131klar\u0131 d\u0131\u015f\u0131nda )\u00a0 15<\/p>\n

    12- Over yoklu\u011fu (iki tarafl\u0131 ve 50 ya\u015f\u0131ndan k\u00fc\u00e7\u00fcklerde)\u00a0\u00a0\u00a0 40<\/p>\n

    13- Ameliyat edilemeyen Prolapsus Uteri\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

    14- Tedavi edilemeyen rektovaginal fist\u00fcller\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

    6- \u00dcROLOJ\u0130\u00a0\u00a0 <\/strong>\u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

    1-Nefrektomi<\/p>\n

      \n
    1. a) Di\u011fer b\u00f6brek sa\u011flam 30<\/li>\n
    2. b) Di\u011fer b\u00f6brek ar\u0131zal\u0131<\/li>\n
    3. ba) Bir b\u00f6brek kayb\u0131 ile birlikte di\u011ferinde fonksiyon bozuklu\u011fu olmadan hastalanma 50<\/li>\n
    4. bb) Bir b\u00f6brek kayb\u0131 ile birlikte di\u011ferinde fonksiyon kayb\u0131 80<\/li>\n<\/ol>\n

      2- Nefropatiler<\/p>\n

      B\u00f6brek fonksiyon testlerinin sonucuna ve tedaviyi gerektirip gerektirmedi\u011fine g\u00f6re;<\/p>\n

        \n
      1. a) % 10\u2019a kadar ar\u0131zal\u0131 ( tedavi ve takibi gerektirmeyen ) 20<\/li>\n
      2. b) % 10-% 30 ar\u0131zal\u0131 ( s\u0131k tedavi ve devaml\u0131 takip gerektiren) 40<\/li>\n
      3. c) % 30-% 60 ar\u0131zal\u0131 (cerrahi veya devaml\u0131 t\u0131bbi tedavilerle tam kontrol alt\u0131na al\u0131namayan) 60<\/li>\n
      4. d) % 60-% 90 ar\u0131zal\u0131 ( tedaviye ra\u011fmen ar\u0131zalar\u0131 aynen devam eden ) 80<\/li>\n<\/ol>\n

        3- B\u00f6brek transplantasyonu\u00a0\u00a0 80<\/p>\n

        4- B\u00f6brek d\u00fc\u015f\u00fckl\u00fc\u011f\u00fc<\/p>\n

        B\u00f6brek fonksiyonlar\u0131n\u0131 bozmu\u015fsa ( Ar\u0131za a\u011f\u0131rl\u0131k \u00f6l\u00e7\u00fcs\u00fc, nefropatiler i\u00e7in \u00f6ng\u00f6r\u00fclen esaslara g\u00f6re bulunur )<\/p>\n

        5- \u00dcrolojik Hastal\u0131klar<\/p>\n

          \n
        1. a) \u0130\u015fg\u00fcc\u00fcn\u00fc orta dereceye kadar bozacak \u015fekilde fonksiyonel d\u00fczensizlikler yapm\u0131\u015f \u00fcrogenital sistem anomalileri ve hastal\u0131k sekelleri, devaml\u0131 idiyopatik en\u00fcrezis, ameliyatla tedavi ile giderilemeyen penis, \u00fcretra ve prostat hastal\u0131klar\u0131, aras\u0131ra dilatasyon ve sonda kullanmay\u0131 gerektiren \u00fcretra darl\u0131klar\u0131, ge\u00e7ici \u00fcriner diversiyonlar, anterior-posterior hipospadyas 35<\/li>\n
        2. b) Laboratuar bulgular\u0131 ile saptanan ve koruyucu tedavi ile iyile\u015femeyen \u00fcriner sistem t\u00fcberk\u00fclozu, \u00fcreterosigmoidostomi, \u00fcreterokutanostomi ve \u00e7e\u015fitli kal\u0131c\u0131 diversiyonlar, postopertif olu\u015fan \u00fcriner fist\u00fcller, inkontinanslar, ekstrofiya vezika, total epispedyas, devaml\u0131 sistostomi veya sonda kullanmay\u0131 gerektiren ileri derecede \u00fcretra darl\u0131klar\u0131\u00a0\u00a0 80<\/li>\n<\/ol>\n

          6- Penis yoklu\u011fu ( do\u011fu\u015ftan, kaza veya hastal\u0131kta ) 40<\/p>\n

          7- Testis yoklu\u011fu<\/p>\n

            \n
          1. a) Tek tarafl\u0131 testis yoklu\u011fu 10<\/li>\n
          2. b) \u0130ki tarafl\u0131 testis yoklu\u011fu veya her iki testisin atrofisi 40<\/li>\n<\/ol>\n

            8- Penis ve testisin birlikte yoklu\u011fu ve idrar\u0131n s\u00fcrekli akmas\u0131\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            7- \u0130\u00c7 HASTALIKLARI, ENDOKR\u0130N VE METABOL\u0130ZMA HASTALIKLARI<\/strong><\/p>\n

            \u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

            1- Endokrin Hastal\u0131klar\u0131<\/p>\n

            A- Hipotalamik hastal\u0131klar<\/p>\n

            Devaml\u0131 replasman tedavisini gerektirir. Primer ve sekonder<\/p>\n

            Diabetes insipidus (Sekonder olanlarda primer olay da g\u00f6z \u00f6n\u00fcne<\/p>\n

            al\u0131n\u0131r.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            B- Hipofizer hastal\u0131klar<\/p>\n

            a- Geli\u015fim salg\u0131 (STH) fazlal\u0131\u011f\u0131<\/p>\n

            aa- Gigantizm 20<\/p>\n

            ab- Komplikasyonsuz akromegali\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            b- Adrenokortikotrop hormon (ACTH) fazlal\u0131\u011f\u0131na ba\u011fl\u0131 Cushing<\/p>\n

            sendromu ( kal\u0131c\u0131 formu )\u00a0\u00a0\u00a0\u00a0 45<\/p>\n

            c- Hipofizer nanismus\u00a0\u00a0 10<\/p>\n

            d- Hipofizin hormon yetersizlikleri<\/p>\n

            da- Hipopitiutarizm\u00a0\u00a0 50<\/p>\n

            db- Panhipopitiutarizm ( simmond ka\u015feksisi )\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 70<\/p>\n

            C- Tiroid hastal\u0131klar\u0131<\/p>\n

            a- Nod\u00fcler, diff\u00fcz, multinod\u00fcler, toksik guatriler, subakut tiroiditler<\/p>\n

            aa- \u0130yile\u015fmi\u015f 0<\/p>\n

            ab- Kal\u0131c\u0131 hipotiroidi (replasman tedavisi uygulan\u0131r)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 15<\/p>\n

            ac- Kal\u0131c\u0131 hipotiroidi (replasman tedavisine diren\u00e7li)<\/p>\n

            (G\u00fcnl\u00fck 400 mikrogram ve daha fazla Tiroksin gerektirenler) 50<\/p>\n

            ad- Kretinizm\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            ae- Graves-Basedow Hastal\u0131\u011f\u0131 ( komplikasyonsuz )\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

            D- Paratiroid Hastal\u0131klar\u0131<\/p>\n

            a- Hiperparatiroidi<\/p>\n

            aa- Primer hiperparatiroidi\u00a0 20<\/p>\n

            ab- Sekonder Hiperparatiroidi\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            b- Hipoparatiroidi<\/p>\n

            ba- \u0130diopatik Primer Hipoparatiroidi (Replasmanla Kompanse)\u00a0\u00a0 20<\/p>\n

            bb- \u0130diopatik Primer Hipoparatiroidi (Replasmana diren\u00e7li)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

            bc- Sekonder Hipoparatiroidi (Replasmana Kompanse)\u00a0\u00a0 20<\/p>\n

            bd- Sekonder Hipoparatiroidi (Replasmana diren\u00e7li)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

            E- Adrenal hastal\u0131klar\u0131<\/p>\n

            a- \u0130ki tarafl\u0131 hiperplazi ( Hipofizer Adenoma ba\u011fl\u0131 ) 45<\/p>\n

            b- Adrenal korteks yetersizli\u011fi ( Addison hastal\u0131\u011f\u0131 )<\/p>\n

            ba- Replasmanla Kompanse\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25<\/p>\n

            bb- Replasmana diren\u00e7li\u00a0\u00a0\u00a0\u00a0 60<\/p>\n

            (G\u00fcnl\u00fck 60 mg ve daha fazla Hidrokortizon gerektirenler)<\/p>\n

            c- Pirimer hiperaldosteronizm<\/p>\n

            ca- \u0130yile\u015fmi\u015f\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0<\/p>\n

            cb- Kan bas\u0131nc\u0131 normalin \u00fcst\u00fcnde\u00a0 30<\/p>\n

            cc- Cerrahi tedaviden yararlanamayanlar veya inoperabl olanlar\u00a0 80<\/p>\n

            d- Feokromasitomalar<\/p>\n

            da- Postoperatif kontrol alt\u0131nda\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            db- Cerrahi tedaviden yararlanamayanlar veya inoperabl olanlar 80<\/p>\n

            F- Gonad hastal\u0131klar\u0131\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            G- \u0130nterseksualite sendromlar\u0131\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            H- Diabetes mellitus<\/p>\n

            a- Diyet ve oral antidiabetiklerle kontrol alt\u0131na al\u0131nan, fonksiyon<\/p>\n

            bozuklu\u011fu yapmam\u0131\u015f Tip II Diabates mellitus\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            b- Komplikasyon yapmam\u0131\u015f olan, a\u00e7l\u0131k kan \u015fekeri 200 mg\u2019\u0131n<\/p>\n

            alt\u0131nda tutulabilen, ketoz ve hipoglisemi g\u00f6stermeyen Tip I<\/p>\n

            diabetes mellitus\u00a0\u00a0\u00a0 30<\/p>\n

            c- A\u00e7l\u0131k kan \u015fekeri s\u00fcrekli olarak 200 mg\u2019\u0131n alt\u0131nda tutulamayan,<\/p>\n

            ketoz g\u00f6steren Tip I diabetes mellitus\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            II- Metabolizma Hastal\u0131klar\u0131<\/p>\n

            A- Diff\u00fcz primer osteoporoz \u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

            (radyolojik dekalsifikasyonla birlikte spontan k\u0131r\u0131klar, \u015fekil<\/p>\n

            bozukluklar\u0131 yapan)<\/p>\n

            B- Osteomalazi<\/p>\n

            T\u0131bbi tedaviye cevap vermeyen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

            C- Gut hastal\u0131\u011f\u0131<\/p>\n

            a- Komplikasyonsuz\u00a0\u00a0\u00a0 10<\/p>\n

            b- Kronik gut artiriti\u00a0\u00a0\u00a0 30<\/p>\n

            D- Osteogenezis interfekta\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            E- Porfiria ( Do\u011fu\u015ftan eritropoetik porfiri)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 70<\/p>\n

            F- Lipid Metabolizmas\u0131 Bozukluklar\u0131<\/p>\n

            a- Konjenital Formlar\u00a0\u00a0 25<\/p>\n

            (Organ komplikasyonlar\u0131 ayr\u0131ca g\u00f6z \u00f6n\u00fcne al\u0131nmal\u0131d\u0131r.)<\/p>\n

            b- Akkiz Formlar<\/p>\n

            ba- Diyetle Reg\u00fcle\u00a0\u00a0 0<\/p>\n

            bb- Diyet ve ila\u00e7 tedavisi gerektirenler\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

            bc- Diyet ve ila\u00e7 tedavisine diren\u00e7li olanlar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25<\/p>\n

            III- Kalp ve Dola\u015f\u0131m Hastal\u0131klar\u0131<\/p>\n

            A-A\u011f\u0131r eforda fonksiyon k\u0131s\u0131tlamas\u0131 olan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            B-Hafif eforda fonksiyon k\u0131s\u0131tlamas\u0131 olan ( tam dekompanse ) 55<\/p>\n

            C-Dinlenme halinde fonksiyon k\u0131s\u0131tlamas\u0131 olan ( tam dekompanse)\u00a0\u00a0\u00a0\u00a0 70<\/p>\n

            IV- \u0130skemik Kalp Hastal\u0131klar\u0131<\/p>\n

            A- Kronik stabil anjina pektoris\u00a0\u00a0 10<\/p>\n

            B- Anstabil anjina pektoris (akut koroner yetersizli\u011fi, intermedier<\/p>\n

            koroner sendromu, variant anjina vb. )\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            C- Romatizmal kalp hastal\u0131\u011f\u0131 ( bir veya birka\u00e7 kapak afeti)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 55<\/p>\n

            D- Endokardit, miyokardit, perikardit, primer miyokardiopati vb.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 70<\/p>\n

            V- Kalp Ameliyatlar\u0131<\/p>\n

            A- Kapal\u0131 komiss\u00fcrotomi 35<\/p>\n

            B- Kalp kapa\u011f\u0131 protezi\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0 40<\/p>\n

            C- Kal\u0131c\u0131 pacemaker ( kardiak efor kapasitesine g\u00f6re )<\/p>\n

            a- Hafif ( 1,2 ) 40<\/p>\n

            b- A\u011f\u0131r ( 3,4 )\u00a0 70<\/p>\n

            D- Koroner revask\u00fclarizasyonu<\/p>\n

            a- Hafif ( 1,2 ) 40<\/p>\n

            b- A\u011f\u0131r ( 3,4 )\u00a0 70<\/p>\n

            \u00d6z\u00fcr durumuna g\u00f6re<\/p>\n

            \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131<\/p>\n

            oran\u0131 %<\/p>\n

            E- Eforu k\u0131s\u0131tlayan perikardioektomi\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            Ge\u00e7irilmi\u015f stabil miyokart infarkt\u00fcs\u00fc\u00a0\u00a0\u00a0\u00a0\u00a0 55<\/p>\n

            VI- Sistemik hipertansiyonlar<\/p>\n

            A- Komplikasyonu olmayan, labil d\u00f6nemde olan esansiyel<\/p>\n

            hipertansiyonlar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

            B- Gunn belirtileri ( Stad II ), koroner sklerozu, sol ventrik\u00fcl<\/p>\n

            hipertrofisi ile birlikte esansiyel hipertansiyonlar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 45<\/p>\n

            C- Tedavi edilemeyen k\u00f6t\u00fc tabiatl\u0131 hipertansiyonlar\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

            VII- Romatoloji<\/p>\n

            A- Eklem hareketlerinde hafif k\u0131s\u0131tlanmaya ve a\u011fr\u0131ya ra\u011fmen g\u00fcnl\u00fck<\/p>\n

            aktivitelerin t\u00fcm\u00fcyle yap\u0131labildi\u011fi haller\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 0<\/p>\n

            B- G\u00fcnl\u00fck aktivitelerin hastalar\u0131n ancak kendi bak\u0131m\u0131n\u0131 yapabilecek<\/p>\n

            kadar s\u0131n\u0131rlanmas\u0131 hali<\/p>\n

            a- Orta ( ileri derecede hareket k\u0131s\u0131tlanmas\u0131na neden olan ) 35<\/p>\n

            b- A\u011f\u0131r ( ileri derecede ankiloz ve hareket k\u0131s\u0131tlanmas\u0131na neden olan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 65<\/p>\n

            c- Hastan\u0131n yata\u011fa veya tekerlekli iskemleye ba\u011f\u0131ml\u0131 kalmas\u0131 hali\u00a0 80<\/p>\n

            VIII- Kollagen Doku Hastal\u0131klar\u0131<\/p>\n

            A- Wegener gran\u00fclomatozisi ( tedaviye cevap vermeyen )\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            B- Periartiritis nodose ( poliariritis )\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            C- Sistemik lupus eritematozis\u00a0\u00a0\u00a0 60<\/p>\n

            D- Komplikasyonlu ve a\u011f\u0131r sistemik lupus eritematozis 80<\/p>\n

            E- Progresif sistemik sklerozis\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

            F- Dermatomyozitis ( 1 y\u0131ll\u0131k kontrol\u00fc gerektirir )\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            8- S\u0130ND\u0130R\u0130M S\u0130STEM\u0130 ARIZALARI <\/strong>\u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

            1- Pankreas hastal\u0131klar\u0131 ( Kronik Pankreatitler )<\/p>\n

            a- Orta derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 45<\/p>\n

            b- A\u011f\u0131r derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 75<\/p>\n

            2- Kronik hepatitler ( cinsine, aktivitesine ve fonksiyon bozuklu\u011funa g\u00f6re)<\/p>\n

            a- Hafif derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            b- Orta derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

            c- A\u011f\u0131r derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 100<\/p>\n

            3- Aktivitesi ve Fonksiyon bozuklu\u011funa g\u00f6re Karaci\u011fer Sirozu :<\/p>\n

            a- Hafif derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            b- A\u011f\u0131r derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            c- Portalstaz veya Shunt ameliyatlar\u0131ndan sonra\u00a0\u00a0 100<\/p>\n

            4- Colitis \u00dclseroza, regional enteritis<\/p>\n

            a- Hafif derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            b- Orta derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

            c- A\u011f\u0131r derece\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 70<\/p>\n

            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0<\/strong><\/p>\n

            9- HEMATOLOJ\u0130K HASTALIKLAR\u00a0\u00a0 <\/strong>\u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

            1-ANEML\u0130LER<\/p>\n

            a-Myelodisplazik Sendromlar (kontrolu gerektirlen)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            A\u011f\u0131r veya terminel olgular\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            b-Aplastik Anemi<\/p>\n

            1- Orta (kontrolu gerekir)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            2- A\u011f\u0131r\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            c-Hemolitik Anemliler<\/p>\n

            1-Eritrosit enzim defektleri,membran defektleri\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

            A\u011f\u0131r veya terminal olgular\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            2-Paroksismel Nokturnal Hemoglobin\u00fcri\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            A\u011f\u0131r veya terminal vakalar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            3-Oto-imm\u00fcn hemolitik anemliler\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            A\u011f\u0131r veya terminal vakalar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            d-Hemoglobinopatiler<\/p>\n

            1-Orak h\u00fccreli anemi \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            A\u011f\u0131r veya terminal safha\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            2-Thalassemi<\/p>\n

            -Minor\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

            -\u0130ntermedia\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            -Major\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            -A\u011f\u0131r veya terminal vaka\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            3-Di\u011ferleri (methemoglobinlere vs.)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

            A\u011f\u0131r veya terminal sahfa\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            ll-POL\u0130STEM\u0130A VERA<\/p>\n

            -Sekonder\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            -Primer\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            -A\u011fr\u0131 terminal safha\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            lll-MYELOF\u0130BROZ\u0130S\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            A\u011fr\u0131 veya terminal safha\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            lV-L\u00d6SEML\u0130LER<\/p>\n

            a-Akut L\u00f6semliler<\/p>\n

            1-Tam remisyonda\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            2-Remisyona girmeyen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            3-Kemik il\u011fi transplantasyonlu (Remisyonda)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            b-Kronik L\u00f6semliler<\/p>\n

            1-Kronik myelositik l\u00f6semi<\/p>\n

            -Kronik faz\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            -Blastik faz\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            2-Kronik lenfositik l\u00f6semi<\/p>\n

            -Evre l-ll (Remisyonda)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            -Evre lll-lV Remisyonda olu\u015fan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            -A\u011f\u0131r terminal vakalar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            c-Monoklonal Gamapatiler<\/p>\n

            -Benign gamapatiler\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

            -Malign gamapatiler\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            -A\u011f\u0131r ve Remisyona girmeyen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            V-KOAG\u00dcLASYON VE HEMOSTAZ BOZUKLUKLARI<\/p>\n

            a-Hemorajik diatezler\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5<\/p>\n

            1-Allerjik purpura\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5<\/p>\n

            2-Di\u011fer vask\u00fclitler<\/p>\n

            b-Trombosit hastal\u0131klar\u0131<\/p>\n

            1-\u0130mm\u00fcn trombositopenik purpura<\/p>\n

            -Akut (kontrol\u00fc gerekir)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

            -Kronik \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            -Refrkter\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            2-Kalitatif trombosit hastal\u0131klar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            -Kalitatif trombosit hastal\u0131klar\u0131n cevap vermeyenleri\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            c-Koagulopatiler (Hemofili, von willebrand hastal\u0131\u011f\u0131 vs)<\/p>\n

            -Fakt\u00f6r aktivitesi %20’nin \u00fcst\u00fc\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            -Fakt\u00f6r aktivitesi %20’nin alt\u0131\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            d-Do\u011fal antikaog\u00fclan eksikli\u011fi (Herediter)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            e-Dissenmine intravaskuler koagulopati\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            Vl-LENFOMALAR<\/p>\n

            a-Hodkgin Lenfoma<\/p>\n

            -Evre l-ll Remisyonda\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            Remisyona girmeyen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            -Evre lll-lV Remisyonda<\/p>\n

            Remisyona girmeyen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            b-Hon Hodkgin Lenfoma<\/p>\n

            -D\u00fc\u015f\u00fck grade Remisyonda \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

            Remisyonda girmeyen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            -\u0130ntermediate veya y\u00fcksek grade<\/p>\n

            Remisyonda\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

            Remisyona girmeyen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

            \u00a0<\/strong><\/p>\n

            \u00a0<\/strong><\/p>\n

            \u00a0<\/strong><\/p>\n

            10- ORTAPED\u0130K VE TRAVMATOLOJ\u0130K ARIZALAR<\/strong>
            \n\u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %
            \n1- Osteomiyelit (aktivitesine, geni\u015fli\u011fine, fonksiyon
            \nbozuklu\u011funa g\u00f6re Balthazard form\u00fcl\u00fc ile ekleme yap\u0131l\u0131r.) 10<\/p>\n

            2- Omuz eklemi ankilozu (fonksiyonel pazisyonda) 20
            \n\u0130ki tarafl\u0131 olursa (fonksiyonel pozisyonda) 40
            \nOmuz eklemi ankilozu (fonksiyonel pazisyonda de\u011fil) 40
            \n\u0130ki tarafl\u0131 olursa (fonksiyonel pazisyonda de\u011fil) 50<\/p>\n

            3- Her iki kolun veya her iki elin kayb\u0131 95<\/p>\n

            4- Bir kolun torasik, k\u00fcrek kemi\u011fi hizas\u0131nda veya \u00e7ok k\u0131sa \u00fcst
            \nkol stumpfu ile amputasyonu 60<\/p>\n

            5- \u00dcst koldan veya dirsek ekleminden amputasyon 50<\/p>\n

            6- \u00d6n koldan amputasyon 50<\/p>\n

            7- Humerus ps\u00f6doartrozu (tedavi edilemeyen) 40<\/p>\n

            8- \u00d6n kol rotasyon hareketleri dahil dirsek eklem ankilozu 20<\/p>\n

            9- Dirsek ekleminde hareket k\u0131s\u0131tl\u0131l\u0131\u011f\u0131 (fonksiyon bozuklu\u011fu yapan) 30<\/p>\n

            10- Dirse\u011fin sarsak eklemi 30<\/p>\n

            11- \u00d6n kol ps\u00f6doartrozu (tedavi edilemeyen) 40<\/p>\n

            12- Kom\u015fu eklemlerde fonksiyon bozuklu\u011fu yapan, e\u011frili olan
            \niyile\u015fmemi\u015f radius veya ulna k\u0131r\u0131\u011f\u0131 20<\/p>\n

            13- El bile\u011fi hareketlerinde k\u0131s\u0131tl\u0131l\u0131k 10<\/p>\n

            14- El bile\u011fi ankilozu
            \na- Uygun pozisyonda 10
            \nb- Uygun olmayan pozisyonda 20<\/p>\n

            15- Ba\u015f parmak hari\u00e7 bir parmak hareketini sekonder olarak
            \nk\u0131s\u0131tlayan k\u00f6t\u00fc, iyile\u015fmemi\u015f bir veya birka\u00e7 metakarpal
            \nkemi\u011fin k\u0131r\u0131\u011f\u0131 10<\/p>\n

            16- Red\u00fckte edilemeyen omuz \u00e7\u0131k\u0131\u011f\u0131 (Fonksiyon bozuklu\u011fu varsa) 25<\/p>\n

            17- Habituel omuz \u00e7\u0131k\u0131\u011f\u0131 (tedaviye cevap vermeyen) 20<\/p>\n

            18- Kol ve \u00f6n kol paralizileri
            \na- Bir kolun total paralizisi 40
            \nb- Yukar\u0131 tip radikuler paralizi (Erb) 30
            \nc- A\u015fa\u011f\u0131 tip radikuler paralizi (Klumpke) 35
            \nd- N.Aksillaris paralizisi (Deltoid) 10
            \ne- N.Radialis paralizisi 20
            \nf- N.Medianus paralizisi 20
            \ng- N.Ulnaris paralizisi 20
            \n* Birden fazla sinirin paralizisi halinde Balthazard form\u00fcl\u00fc
            \nuygulan\u0131r.
            \n* \u0130kiden fazla sinir hasar\u0131nda monopleji say\u0131l\u0131r.<\/p>\n

            19- El parmak ar\u0131zalar\u0131
            \nI-A- Ba\u015f parmak Amp\u00fctasyonu
            \na- Karpo-metakarpal eklemden
            \naa- Tek tarafl\u0131 24
            \nab- \u0130ki tarafl\u0131 30
            \nb- Meta-Karpo-falangeal eklemden
            \nba- Tek tarafl\u0131 20
            \nbb- \u0130ki tarafl\u0131 26
            \nc- Falango-falangeal eklemden
            \nca- Tek tarafl\u0131 16
            \ncb- iki tarafl\u0131 22
            \nB- Ba\u015fparmak sertlikleri, ankilozlar\u0131
            \na- Karpo-metakarpal eklemden
            \naa- Tek tarafl\u0131 13
            \nab- \u0130ki tarafl\u0131 16
            \nb- Metakarpo-falangeal eklemden
            \nba- Tek tarafl\u0131 10
            \nbb- \u0130ki tarafl\u0131 13
            \nc- Falango-falangeal eklemden
            \nca- Tek tarafl\u0131 7
            \ncb- \u0130ki tarafl\u0131 10<\/p>\n

            II-A- \u0130\u015faret parma\u011f\u0131 amp\u00fctasyonu
            \na- Karpo-metakarpal eklemden
            \naa- Tek tarafl\u0131 7
            \nab- \u0130ki tarafl\u0131 10
            \nb- Metakarpo-falangeal eklemden
            \nba- Tek tarafl\u0131 7
            \nbb- \u0130ki tarafl\u0131 10
            \nc- Falango-Falangeal eklemden
            \nca- Tek tarafl\u0131 6
            \ncb- \u0130ki tarafl\u0131 9
            \nd- Distal \u0130nterfalangeal eklemden
            \nda- Tek tarafl\u0131 2
            \ndb- \u0130ki tarafl\u0131 5
            \nB- \u0130\u015faret parma\u011f\u0131 sertlikleri, ankilozlar\u0131
            \na- Karpo-metakarpal eklemden
            \naa- Tek tarafl\u0131 4
            \nab- \u0130ki tarafl\u0131 7
            \nb- Metakarpo-falangeal eklemden
            \nba- Tek tarafl\u0131 4
            \nbb- \u0130ki tarafl\u0131 7
            \nc- Falango-falangeal eklemden
            \nca- Tek tarafl\u0131 2
            \ncb- \u0130ki tarafl\u0131 5
            \nd- Distal \u0130nterfalangeal eklemden
            \nda- Tek tarafl\u0131 2
            \ndb- \u0130ki tarafl\u0131 5<\/p>\n

            III-A- Orta parmak amputasyonu
            \na- Karpo-metakarpal eklemden
            \naa- Tek tarafl\u0131 5
            \nab- \u0130ki tarafl\u0131 8
            \nb- Metakarpo-falangeal eklemden
            \nba- Tek tarafl\u0131 5
            \nbb- \u0130ki tarafl\u0131 8
            \nc- Falango-falangeal eklemden
            \nca- Tek tarafl\u0131 3
            \ncb- \u0130ki tarafl\u0131 6
            \nd-Distal \u0130nterfalangeal eklemden
            \nda-Tek tarafl\u0131 1
            \ndb-\u0130ki tarafl\u0131 3
            \nB-Orta parmak sertlikleri, ankilozlar\u0131
            \na-Karpo-metakarpal eklemden
            \naa-Tek tarafl\u0131 5
            \nab-\u0130ki tarafl\u0131 8
            \nb-Metakarpo-falangeal eklemden
            \nba-Tek tarafl\u0131 5
            \nbb-\u0130ki tarafl\u0131 8
            \nc-Falango-falangeal eklemden
            \nca-Tek tarafl\u0131 1
            \ncb-\u0130ki tarafl\u0131 4
            \nd-Distal \u0130nterfalangeal eklemden
            \nda-Tek tarafl\u0131 1
            \ndb-\u0130ki tarafl\u0131 2<\/p>\n

            IV-A-Y\u00fcz\u00fck parma\u011f\u0131 amputasyonu
            \na-Karpo-metakarpal eklemden
            \naa-Tek tarafl\u0131 3
            \nab-\u0130ki tarafl\u0131 6
            \nb-Metakarpo-falangeal eklemden
            \nba-Tek tarafl\u0131 3
            \nbb-\u0130ki tarafl\u0131 6
            \nc-Falango-falangeal eklemden
            \nca-Tek tarafl\u0131 1
            \ncb-\u0130ki tarafl\u0131 4
            \nd-Distal \u0130nterfalangeal eklemden
            \nda-Tek tarafl\u0131 1
            \ndb-\u0130ki tarafl\u0131 2
            \nB-Y\u00fcz\u00fck parma\u011f\u0131 sertlikleri, ankilozlar\u0131
            \na-Karpo-metakarpal eklemden
            \naa-Tek tarafl\u0131 1
            \nab-\u0130ki tarafl\u0131 4
            \nb-Metakarpo-falangeal eklemden
            \nba-Tek tarafl\u0131 1
            \nbb-\u0130ki tarafl\u0131 4
            \nc-Falango-falangeal eklemden
            \nca-Tek tarafl\u0131 1
            \ncb-\u0130ki tarafl\u0131 3
            \nd-Distal \u0130nterfalangeal eklemden
            \nda-Tek tarafl\u0131 1
            \ndb-\u0130ki tarafl\u0131 2<\/p>\n

            V- A-K\u00fc\u00e7\u00fck parmak amputasyonu
            \na-Karpo-metakarpal eklemden
            \naa-Tek tarafl\u0131 2
            \nab-\u0130ki tarafl\u0131 5
            \nb-Metakarpo-falangeal eklemden
            \nba-Tek tarafl\u0131 2
            \nbb-\u0130ki tarafl\u0131 5
            \nc-falango-falangeal eklemden
            \nca-Tek tarafl\u0131 1
            \ncb-\u0130ki tarafl\u0131 4
            \nd-Distal \u0130nterfalangeal eklemden
            \nda-Tek tarafl\u0131 1
            \ndb-\u0130ki tarafl\u0131 2
            \nB-K\u00fc\u00e7\u00fck parmak sertlikleri, ankilozlar\u0131
            \na-Karpo-metakarpal eklemde
            \naa-Tek tarafl\u0131 1
            \nab-\u0130ki tarafl\u0131 4
            \nb-Metakarpo-falangeal eklemde
            \nba-Tek tarafl\u0131 1
            \nbb-\u0130ki tarafl\u0131 4
            \nc-Falango-falangeal eklemde
            \nca-Tek tarafl\u0131 1
            \ncb-\u0130ki tarafl\u0131 3
            \nd-Distal \u0130nterfalangeal eklemde
            \nda-Tek tarafl\u0131 1
            \ndb-\u0130ki tarafl\u0131 2<\/p>\n

            VI-A-Ba\u015fparmak ve i\u015faret parma\u011f\u0131n\u0131n birlikte amputasyonlar\u0131
            \na-Karpo-metakarpal veya metakarpofalangeal eklemden
            \naa-Tek tarafl\u0131 30
            \nab-\u0130ki tarafl\u0131 45
            \nb-Falango-falangeal eklemden
            \nba-Tek tarafl\u0131 20
            \nbb-\u0130ki tarafl\u0131 30
            \nB-Ba\u015fparmak ve i\u015faret parma\u011f\u0131n\u0131n birlikte sertlikler,ankilozlar\u0131
            \na-Metakarpo-Falangeal eklemde
            \naa-Tek tarafl\u0131 23
            \nab-\u0130ki tarafl\u0131 28
            \nb-Falango-falangeal eklemden
            \nba-Tek tarafl\u0131 13
            \nbb-\u0130ki tarafl\u0131 18<\/p>\n

            VII-A-Ba\u015fparmak,i\u015faret parma\u011f\u0131 ve orta parma\u011f\u0131n birlikte amputasyonlar\u0131
            \na-Karpo-metakarpol veya metakarpo-falangeal eklemden
            \naa-Tek tarafl\u0131 35
            \nab-\u0130ki tarafl\u0131 50
            \nb-Falango-falangea eklemden
            \nba-Tek tarafl\u0131 22
            \nbb-\u0130ki tarafl\u0131 32
            \nB-Ba\u015fparmak,i\u015faretparma\u011f\u0131 ve orta parma\u011f\u0131n birlikte sertlikleri,
            \nankilozlar\u0131
            \na-Metakarpo-falangeal eklemde
            \naa-Tek tarafl\u0131 30
            \nab-\u0130ki tarafl\u0131 35
            \nb-Falango-falangeal eklemde
            \nba-Tek tarafl\u0131 15
            \nbb-\u0130ki tarafl\u0131 20<\/p>\n

            VIII-A-Ba\u015fparmak,i\u015faret parma\u011f\u0131,orta parmak ve y\u00fcz\u00fck parma\u011f\u0131n\u0131n
            \nbirlikte amputasyonlar\u0131
            \na-Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa-Tek tarafl\u0131 40
            \nab-\u0130ki tarafl\u0131 60
            \nb-Falango-falangoel eklemden
            \nba-Tek tarafl\u0131 30
            \nbb-\u0130ki tarafl\u0131 35
            \nB-Ba\u015fparmak,i\u015faret parma\u011f\u0131,orta parmak ve y\u00fcz\u00fck parma\u011f\u0131n\u0131n
            \nbirlikte sertlikleri, ankilozlar\u0131
            \na-Metakarpo-falangeal eklemde
            \naa-Tek tarafl\u0131 35
            \nab-\u0130ki tarafl\u0131 40
            \nb-Falango-falangeal eklemden
            \nba-Tek tarafl\u0131 27
            \nbb-\u0130ki tarafl\u0131 32<\/p>\n

            IX-A-Ba\u015fparmak,i\u015faret parma\u011f\u0131,orta parmak ve y\u00fcz\u00fck parma\u011f\u0131 ve k\u00fc\u00e7\u00fck
            \nparma\u011f\u0131n birlikte amputasyonlar\u0131
            \na-Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa-Tek tarafl\u0131 43
            \nab-\u0130ki tarafl\u0131 60
            \nb-Falango-falangeal eklemden
            \nba-Tek tarafl\u0131 33
            \nbb-\u0130ki tarafl\u0131 38
            \nB-Ba\u015fparmak,i\u015faret parma\u011f\u0131,orta parmak,y\u00fcz\u00fck parma\u011f\u0131 ve k\u00fc\u00e7\u00fck
            \nparma\u011f\u0131n birlikte sertlikleri,ankilozlar\u0131
            \na-Metakarpo-falangeal eklemde
            \naa-Tek tarafl\u0131 40
            \nab-\u0130ki tarafl\u0131 46
            \nb-Falango-falangeal eklemde
            \nba-Tek tarafl\u0131 23
            \nbb-\u0130ki tarafl\u0131 28<\/p>\n

            X-A-\u0130\u015faret parma\u011f\u0131 ve orta parma\u011f\u0131n birlikte amputasyonlar\u0131
            \na-Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa-Tek tarafl\u0131 20
            \nab-\u0130ki tarafl\u0131 30
            \nb-Falango-falangeal eklemden
            \nba-Tek tarafl\u0131 6
            \nbb-\u0130ki tarafl\u0131 10
            \nc-Distal \u0130nterfalangeal eklemden
            \nca-Tek tarafl\u0131 3
            \ncb-\u0130ki tarafl\u0131 5
            \nB-\u0130\u015faret parma\u011f\u0131 ve orta parma\u011f\u0131n birlikte sertlikleri,ankilozlar\u0131
            \na-Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa-Tek tarafl\u0131 13
            \nab-\u0130ki tarafl\u0131 18
            \nb-Falango-falangeal eklemden
            \nba-Tek tarafl\u0131 4
            \nbb-\u0130ki tarafl\u0131 9
            \nc-Distal \u0130nterfalangeal eklemden
            \nca-Tek tarafl\u0131 3
            \ncb-\u0130ki tarafl\u0131 5<\/p>\n

            XI-A-\u0130\u015faret parma\u011f\u0131,orta parmak ve y\u00fcz\u00fck parma\u011f\u0131n\u0131n birlikte
            \namputasyonlar\u0131
            \na-Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa-Tek tarafl\u0131 28
            \nab-\u0130ki tarafl\u0131 35
            \nb-Falango-falangeal eklemden
            \nba-Tek tarafl\u0131 16
            \nbb-\u0130ki tarafl\u0131 20
            \nc-Distal \u0130nterfalangeal eklemden
            \nca-Tek tarafl\u0131 4
            \ncb-\u0130ki tarafl\u0131 9
            \nB-\u0130\u015faret parma\u011f\u0131,orta parmak ve y\u00fcz\u00fck parma\u011f\u0131n\u0131n birlikte
            \nsertlikleri,ankilozlar\u0131
            \na-Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa-Tek tarafl\u0131 23
            \nab-\u0130ki tarafl\u0131 30
            \nb-Falango-falangeal eklemden
            \nba-Tek tarafl\u0131 10
            \nbb-\u0130ki tarafl\u0131 15
            \nc-Distal \u0130nterfalangeal eklemden
            \nca-Tek tarafl\u0131 4
            \ncb-\u0130ki tarafl\u0131 6<\/p>\n

            XII-A-\u0130\u015faret parma\u011f\u0131,orta parmak,y\u00fcz\u00fck parma\u011f\u0131 ve k\u00fc\u00e7\u00fck parma\u011f\u0131n
            \nbirlikte amputasyonlar\u0131
            \na-Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa-Tek tarafl\u0131 35
            \nab-\u0130ki tarafl\u0131 57
            \nb-Falango-falangeal eklemden
            \nba-Tek tarafl\u0131 18
            \nbb-\u0130ki tarafl\u0131 25
            \nc-Distal \u0130nterfalangeal eklemden
            \nca-Tek tarafl\u0131 5
            \ncb-\u0130ki tarafl\u0131 11
            \nB-\u0130\u015faret parma\u011f\u0131, orta parmak, y\u00fcz\u00fck parma\u011f\u0131 ve k\u00fc\u00e7\u00fck parma\u011f\u0131n
            \nbirlikte sertlikleri, ankilozlar\u0131
            \na-Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa-Tek tarafl\u0131 25
            \nab-\u0130ki tarafl\u0131 31
            \nb-Falango-falangeal eklemden
            \nba- Tek tarafl\u0131 11
            \nbb- \u0130ki tarafl\u0131 16
            \nc- Distal \u0130nterfalangeal eklemden
            \nca- Tek tarafl\u0131 5
            \ncb- \u0130ki tarafl\u0131 8<\/p>\n

            XIII-A- Orta parmak ve y\u00fcz\u00fck parma\u011f\u0131n\u0131n birlikte amputasyonlar\u0131
            \na- Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa- Tek tarafl\u0131 15
            \nab- \u0130ki tarafl\u0131 20
            \nb- Falango-falangeal eklemden
            \nba- Tek tarafl\u0131 5
            \nbb- \u0130ki tarafl\u0131 9
            \nc- Distal \u0130nterfalangeal eklemden
            \nca- Tek tarafl\u0131 3
            \ncb- \u0130ki tarafl\u0131 5
            \nB- Orta parmak ve y\u00fcz\u00fck parma\u011f\u0131n\u0131n birlikte sertlikleri, ankilozlar\u0131
            \na- Karpo-metakarpal veya metakarpo-falangeal-eklemde
            \naa- Tek tarafl\u0131 11
            \nab-\u0130ki tarafl\u0131 16
            \nb- Falango-falangeal eklemden
            \nba- Tek tarafl\u0131 4
            \nbb- \u0130ki tarafl\u0131 9
            \nc- Distal \u0130nterfalangeal eklemden
            \nca- Tek tarafl\u0131 3
            \ncb- \u0130ki tarafl\u0131 5<\/p>\n

            XIV-A-Orta parmak, y\u00fcz\u00fck parma\u011f\u0131 ve k\u00fc\u00e7\u00fck parma\u011f\u0131n
            \nbirlikte amputasyonlar\u0131
            \na- Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa- Tek tarafl\u0131 25
            \nab- \u0130ki tarafl\u0131 40
            \nb- Falango-falangeal eklemden
            \nba- Tek tarafl\u0131 13
            \nbb- \u0130ki tarafl\u0131 20
            \nc- Distal \u0130nterfalangeal eklemden
            \nca- Tek tarafl\u0131 3
            \ncb- \u0130ki tarafl\u0131 7
            \nB- Orta parmak, y\u00fcz\u00fck parma\u011f\u0131 ve k\u00fc\u00e7\u00fck parma\u011f\u0131n
            \nbirlikte sertlikleri, ankilozlar\u0131
            \na- Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa- Tek tarafl\u0131 14
            \nab- \u0130ki tarafl\u0131 31
            \nb- Falango-falangeal eklemden
            \nba- Tek tarafl\u0131 7
            \nbb- \u0130ki tarafl\u0131 13
            \nc- Distal \u0130nterfalangeal eklemden
            \nca- Tek tarafl\u0131 3
            \ncb- \u0130ki tarafl\u0131 5<\/p>\n

            XV-A- Y\u00fcz\u00fck parma\u011f\u0131 ve k\u00fc\u00e7\u00fck parma\u011f\u0131n birlikte amputasyonlar\u0131
            \na- Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa- Tek tarafl\u0131 13
            \nab- \u0130ki tarafl\u0131 20
            \nb-Falango-falangeal eklemden
            \nba- Tek tarafl\u0131 9
            \nbb- \u0130ki tarafl\u0131 16
            \nc- Distal \u0130nterfalangeal eklemden
            \nca- Tek tarafl\u0131 2
            \ncb-\u0130ki tarafl\u0131 4
            \nB- Y\u00fcz\u00fck parna\u011f\u0131 ve k\u00fc\u00e7\u00fck parma\u011f\u0131n birlikte sertlikleri,
            \nankilozlar\u0131
            \na- Karpo-metakarpal veya metakarpo-falangeal eklemden
            \naa- Tek tarafl\u0131 9
            \nab- \u0130ki tarafl\u0131 13
            \nb- Falango-falangeal eklemden
            \nba- Tek tarafl\u0131 3
            \nbb- \u0130ki tarafl\u0131 9
            \nc-Distal \u0130nterfalangeal eklemden
            \nca- Tek tarafl\u0131 1
            \ncb- \u0130ki tarafl\u0131<\/p>\n

            XVI- \u015eekil bozuklu\u011fu yapan metakarp k\u0131r\u0131klar\u0131
            \nA- 1-2 metakarp k\u0131r\u0131\u011f\u0131
            \na-Tek tarafl\u0131 5
            \nb-\u0130ki tarafl\u0131 10
            \nB-2’den fazla metakarp k\u0131r\u0131\u011f\u0131
            \na- Tek tarafl\u0131 10
            \nb- \u0130ki tarafl\u0131 18<\/p>\n

            20- Bir elin tam kayb\u0131 50<\/p>\n

            21- \u0130ki elin tam kayb\u0131 80<\/p>\n

            22- Wolkman kontrakt\u00f6r\u00fc
            \na) Hafif derecede 10
            \nb) Orta derecede 20
            \nc) A\u011f\u0131r derecede 40<\/p>\n

            23- Uyluktan her iki baca\u011f\u0131n kayb\u0131 80<\/p>\n

            24- Bir baca\u011f\u0131n uyluktan di\u011ferinin tibiadan kayb\u0131 80<\/p>\n

            25- Bir alt extremite ve bir \u00fcst extremitenin kayb\u0131 80<\/p>\n

            26- Bir baca\u011f\u0131n kal\u00e7adan veya \u00e7ok k\u0131sa stumpflu kayb\u0131 60<\/p>\n

            27- Stumpfun ve eklemlerin yeterli fonksiyonlar\u0131 ko\u015fuluyla
            \ntibiadan amputasyon 40<\/p>\n

            28- Stumpfun ve eklemlerin yetersiz fonksiyonda tibiadan
            \nbacak kayb\u0131 45<\/p>\n

            29- Tibiadan her iki baca\u011f\u0131n kayb\u0131
            \na-) Fonksiyonel g\u00fcd\u00fckl\u00fc 70
            \nb) Yetersiz g\u00fcd\u00fckl\u00fc 80<\/p>\n

            30- Aya\u011f\u0131n k\u0131smi kayb\u0131
            \na) Talus kalkaneusun korundu\u011fu amputasyon
            \n1- Tek tarafl\u0131, stumpfiyi 30
            \n2- \u0130ki tarafl\u0131 40
            \nb) Tarsometatarsal eklemden amputasyon
            \n1-Tek tarafl\u0131 25
            \n2-\u0130ki tarafl\u0131 40<\/p>\n

            31-Aya\u011f\u0131n Lisfrano veya Sharp’a g\u00f6re amputasyonu
            \na)Tek tarafl\u0131, stumpfiyi 20
            \nb)\u0130ki tarafl\u0131 35<\/p>\n

            32-Bir ayak parma\u011f\u0131 kayb\u0131
            \na)Ba\u015fparma\u011f\u0131n kayb\u0131 5
            \nNot: Her parmak kayb\u0131 i\u00e7in Balthazard ile % 1 eklenir.
            \nb) Bir aya\u011f\u0131n t\u00fcm parmaklar\u0131n\u0131n kayb\u0131 10
            \nc) \u0130ki aya\u011f\u0131n t\u00fcm parmaklar\u0131n\u0131n kayb\u0131 20<\/p>\n

            33-Posizyonuna g\u00f6re her iki kal\u00e7an\u0131n ankilozu 70<\/p>\n

            34-Tek kal\u00e7a ekleminin ankilozu 40<\/p>\n

            35-Endoprotezlerde 30<\/p>\n

            36-Sarsak kal\u00e7a 40<\/p>\n

            37-Uyluk Ps\u00f6doartrozu (tedaviye cevap vermeyen) 40<\/p>\n

            38-K\u0131sal\u0131kla iyile\u015fmi\u015f femur k\u0131r\u0131\u011f\u0131:
            \na)K\u0131sal\u0131k 3-6 cm.ye kadar 10
            \nb)K\u0131sal\u0131k 6-10 cm.den fazla 20<\/p>\n

            39-Bir diz ekleminde ankiloz 40
            \na) Uygun pozisyonda
            \n1-Tek tarafl\u0131 20
            \n2-\u0130ki tarafl\u0131 40
            \nb)Uygun olmayan pozisyonda
            \n1-Tek tarafl\u0131 40
            \n2-\u0130ki tarafl\u0131 60<\/p>\n

            40-Patella k\u0131r\u0131\u011f\u0131
            \na)Ekstansiyon yapabilen ps\u00f6doartroz 10
            \nb)Ekstansiyona engel ps\u00f6doartroz 20<\/p>\n

            41-X-bein,O-bein,genu recurvatum (eklemde fonksiyon bozuklu\u011fu yapan) 20<\/p>\n

            42-Diz ekleminde hareket k\u0131s\u0131tl\u0131\u011f\u0131
            \na)Fonksiyon bozuklu\u011fu yapmayan 0
            \nb)Fonksiyon bozuklu\u011fu yapan 20
            \n*\u00c7ift tarafl\u0131ysa Balthazard form\u00fcl\u00fc uygulan\u0131r.<\/p>\n

            43-Tibia ps\u00f6doartrozu (tedavi edilemeyen) 40
            \n*\u00c7ift tarafl\u0131ysa Balthazard form\u00fcl\u00fc uygulan\u0131r.<\/p>\n

            44- Yanl\u0131\u015f pozisyonda kaynam\u0131\u015f tibia k\u0131r\u0131\u011f\u0131 15<\/p>\n

            45-Ayak bile\u011fi k\u0131r\u0131\u011f\u0131
            \na)Kemik \u00e7atal\u0131 korunarak iyile\u015fme 0
            \nb)Kemik \u00e7atal\u0131 geni\u015flemi\u015f fibula k\u00f6\u015felenmi\u015f ve sekonder
            \nartrosis deformansl\u0131 20<\/p>\n

            46-Ayak bile\u011fi ankilozu
            \na)Uygun posizyonda 20
            \nb)Uygun olmayan posizyonda
            \n1-Tek tarafl\u0131 25
            \n2-\u0130ki tarafl\u0131 40<\/p>\n

            47-A- a)Artrotik de\u011fi\u015fikli\u011fi olmayan pes planus ve pes cavus 1
            \nb)Artrotik de\u011fi\u015fikli\u011fi olan pes lanus ve pes cavus 10
            \nB-Rigid PEV (opere edilmemi\u015f) 40<\/p>\n

            48-I.den V.parma\u011fa kadar ankiloz, her bir parmak i\u00e7in 1<\/p>\n

            49-Diz ekleminde gev\u015feme:
            \na)Fonksiyon bozuklu\u011fu yapan ba\u011f lezyonlar\u0131 tek tarafl\u0131 30
            \nb)Fonksiyon bozuklu\u011fu yapan ba\u011f lezyonlar\u0131 iki tarafl\u0131 40<\/p>\n

            50-M.Gluteus maksimus felci 10<\/p>\n

            51-M.Gluteus medius ve minimus felci 20<\/p>\n

            52-Kal\u00e7a fleks\u00f6rlerinin felci 30<\/p>\n

            53-N.Femoralis felci 40<\/p>\n

            54-N.\u0130schiadicus felci 40<\/p>\n

            55-N.Tibialis felci 20<\/p>\n

            56-N.Fibularis felci 20<\/p>\n

            57-Y\u00fckleme yetene\u011fini bozan ayak taban eskarlar\u0131 (Hafif) 15<\/p>\n

            58-Topuk ve ayak taban\u0131nda b\u00fcy\u00fck doku kay\u0131plar\u0131ndan sonraki eskarlar 20<\/p>\n

            59-Poliomyelit sekelleri:
            \nA-Yaln\u0131z bir alt ekstremitede olan:
            \n1-Hafif, y\u00fcr\u00fcmeyi bozmayan 20
            \n(adele fonksiyon kayb\u0131 4-5 derece olan)
            \n2-Orta derecede: Adale fonksiyon kayb\u0131 3.dereceden olan 40
            \n3-A\u011f\u0131r derecede: 1.,2.dereceden adale fonksiyon
            \nbozuklu\u011fu olan 50
            \nB-\u0130ki alt ekstremiteyi i\u00e7ine alan:
            \n1-Biri orta,di\u011feri hafif 40
            \n2-\u0130kiside orta olup ancak koltuk de\u011fne\u011fi ile y\u00fcr\u00fcryen 60
            \n3-\u0130kiside ileri derecede olup y\u00fcr\u00fcme \u015fans\u0131 olmayan 80
            \nC-\u00dcst ekstremitelerin birinde:
            \n1-Hafif 15
            \n2-Orta 20
            \n3-A\u011f\u0131r 55
            \nD-\u00dcst ekstremiteler (iki tarafl\u0131)
            \n1-\u0130kiside hafif 35
            \n2-Biri orta di\u011feri hafif 40
            \n3-\u0130kiside orta 60<\/p>\n

            60-Skolyoz:
            \n1-Fonksiyon bozuklu\u011fu yapmayan 20
            \n2-A\u011f\u0131r olup, solunum, dola\u015f\u0131m veya sinirsel bozukluklardan
            \nbirini yapanlar 40<\/p>\n

            61-Kifo-skolyoz 30
            \nSolunum fonksiyon bozuklu\u011fu yapan 45<\/p>\n

            62-Do\u011fu\u015ftan kal\u00e7a \u00e7\u0131k\u0131\u011f\u0131:
            \n1-Bir tarafl\u0131 30
            \n2-\u0130ki tarafl\u0131 45<\/p>\n

            63- Malformasyonlar
            \n1- Do\u011fu\u015ftan \u00e7arp\u0131k ayak
            \na) Tek tarafl\u0131 (hafif) 10
            \nb) Tek tarafl\u0131 (tedaviye cevap vermeyen) 20
            \nc- \u0130ki tarafl\u0131 (y\u00fcr\u00fcmeyi bozu\u015f \u015fekline g\u00f6re)
            \n1) Hafif 30
            \n2) A\u011f\u0131r 40
            \n2- Do\u011fu\u015ftan koksa vara
            \na) Tek tarafl\u0131 20
            \nb) \u0130ki tarafl\u0131 30
            \nc) Perthes sekeli
            \n1) Hafif 10
            \n2) Orta 20
            \n3) A\u011f\u0131r 30<\/p>\n

            64- Spondilit Rizomelik: (her y\u0131l yeniden muayene kayd\u0131yla)
            \n1- Orta 40
            \n2- A\u011f\u0131r 60<\/p>\n

            65- Romatoid Artirit
            \n1- Orta 40
            \n2- A\u011f\u0131r 60<\/p>\n

            11- DER\u0130 HASTALIKLARI<\/strong>\u00a0\u00a0\u00a0\u00a0 \u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

            1-Psoriazais vulgaris<\/p>\n

            Bu guruptaki hastalar (Eklem tutulumlu hari\u00e7) 1 y\u0131ll\u0131k<\/p>\n

            kontrollerde de\u011ferlendirilir.<\/p>\n

            A-V\u00fccudun %20-50’sini kapsayan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

            b- V\u00fccudun %50-80’sini kapsayan\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

              \n
            • c- Eklem tutulumu ayr\u0131ca de\u011ferlendirilir.<\/li>\n<\/ul>\n

              2-Eksfolyatif dermatitler (Eritd-rodermiler)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              Bu guruptaki hastalar 1y\u0131ll\u0131k kontrollerle de\u011ferlendirilir.Altta yatan<\/p>\n

              hastal\u0131k varsa ayr\u0131ca de\u011ferllendirilir.<\/p>\n

              3-Jeneralize p\u00fcs\u00fctler psoriazis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              Bu guruptaki hastalar 1 y\u0131ll\u0131k kontrollerle de\u011ferlendirilir.<\/p>\n

              4-\u0130nat\u00e7\u0131 palmoplanter er\u00fcpsiyonlar<\/p>\n

              -Akrodermatitis kontinua<\/p>\n

              -Palmoplantar p\u00fcst\u00fclozis<\/p>\n

              Bu guruptaki hastalarda ar\u0131zan\u0131n derecesi ve s\u00fcresi alt\u0131 ayl\u0131k<\/p>\n

              kontroller ile saptan\u0131r.<\/p>\n

              a-Hafif \u015fiddette \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

              b-Orta \u015fiddette \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              c-Ciddi seyirli hastal\u0131kta \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              5-Palmoplanter keratodermiler<\/p>\n

              A-Herediter tipte olanlar : ( Unna Thost,Mal de Melada vs.)<\/p>\n

              a-Orta \u015fiddette \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25<\/p>\n

              b-Ciddi seyirde \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

              c-Mutilasyon yap\u0131c\u0131 (Vohnwinkel)formda eksrmite fonksiyon<\/p>\n

              kayb\u0131 da hesaplan\u0131r.<\/p>\n

              B-Geni\u015f yer kaplayan tedaviye diren\u00e7li verr\u00fc ve kalluslar:<\/p>\n

              Bir y\u0131ll\u0131k kontroller ile ar\u0131za derecesi saptan\u0131r.<\/p>\n

              a-Orta \u015fiddette \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              b-Ciddi seyirli hastal\u0131kta\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

              6-Otoimm\u00fcn vezik\u00fclob\u00fcll\u00f6z ve p\u00fcst\u00fcler hastal\u0131klar<\/p>\n

              – Pemfigus grubu hastal\u0131klar<\/p>\n

              – Pemfigoid grubu hastal\u0131klar<\/p>\n

              – Duhring hastal\u0131\u011f\u0131<\/p>\n

              – Di\u011ferleri<\/p>\n

              Bu grup hastal\u0131klarda ar\u0131za derecesi bir y\u0131ll\u0131k kontrollerle saptan\u0131r.<\/p>\n

              a- Hafif \u015fiddette\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              b- Orta \u015fiddette\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              c- Ciddi seyirli hastal\u0131kta\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 60<\/p>\n

              7- Di\u011fer herediter deri hastal\u0131klar\u0131<\/p>\n

              A- Epidermolizis b\u00fclloza<\/p>\n

              a-Simpleks\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              Birer y\u0131ll\u0131k kontrollerle ar\u0131za derecesi belirlenir<\/p>\n

              b-Jeneralize benign atrofik epidermolizis b\u00fclloza\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              c-Distrofik formlar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 65<\/p>\n

              B-\u0130ktiyozlar<\/p>\n

              a-\u0130ktiyozis vulgaris\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

              Bir y\u0131ll\u0131k kontrollerle ar\u0131za derecesi belirlenir<\/p>\n

              b-X’e ba\u011fl\u0131 tip \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              Bir y\u0131ll\u0131k kontrollerle ar\u0131za derecesi belirlenir.<\/p>\n

              c-B\u00fcll\u00f6z iktiyoziform eritrodermi\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 65<\/p>\n

              d-Lameller tip\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              8- Lepra<\/p>\n

              a- Erken d\u00f6nemde tan\u0131nan,tedavi alt\u0131ndaki lepra\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              Bir y\u0131ll\u0131k kontrollerle ar\u0131za derecesi belirlenir.<\/p>\n

              b-Sinir tutulumu,trofik de\u011fi\u015fiklikler,g\u00f6z ve i\u00e7 organ bulgular\u0131 varsa<\/p>\n

              ilgili bran\u015fca de\u011ferlendirilir.<\/p>\n

              9- Kutan\u00f6z T h\u00fccreli lenfomalar<\/p>\n

              A- Mikozis fungoides<\/p>\n

              Bu grup hastalar,1 y\u0131ll\u0131k kortrollerle de\u011ferlendirilir.<\/p>\n

              a-Premikotik evre\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              b-\u0130nfilltratif (plak),t\u00fcmoral evre\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 60<\/p>\n

              c-\u0130nternal tutulum oldu\u011funda ilgili bran\u015fca de\u011ferlendirilir.<\/p>\n

              B-Sezary sendromu\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

              \u00a0<\/strong><\/p>\n

              \u00a0<\/strong><\/p>\n

              \u00a0<\/strong><\/p>\n

              12- G\u00d6\u011e\u00dcS HASTALIKLARI VE CERRAH\u0130S\u0130<\/strong><\/p>\n

              \u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

              \u00a0<\/strong><\/p>\n

              1-)Akci\u011fer,plevra ve g\u00f6\u011f\u00fcs kafesi hastal\u0131klar\u0131 veya akci\u011feri tutan<\/p>\n

              di\u011fer t\u00fcm hastal\u0131klarda solunum ve dola\u015f\u0131m fonksiyonunda bozukluk<\/p>\n

              yapm\u0131\u015fsa;<\/p>\n

              a-Az etkilenme varsa\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              b-Orta derecede etkilenme varsa\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              c-A\u011f\u0131r derecede etkilenme varsa\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

              2-)Akci\u011fer T\u00fcberk\u00fclozu;<\/p>\n

              a-Aktif ise (y\u0131ll\u0131k kontrollere g\u00f6re)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 60<\/p>\n

              b-\u0130naktif ise ( 1.maddedeki fonksiyon bozukluklar\u0131na g\u00f6re de\u011ferlendirilir.)<\/p>\n

              3-)Akut T\u00fcberk\u00fcloz Pl\u00f6rezi (ge\u00e7ici s\u00fcreyle)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 60<\/p>\n

              Kronik T\u00fcberk\u00fcloz Pl\u00f6rezi 1. maddeye g\u00f6re de\u011ferlendirilir.<\/p>\n

              4-)Ekstra Pulmoner T\u00fcberk\u00fcloz<\/p>\n

              a-Aktif ise (y\u0131ll\u0131k kontrollere g\u00f6re)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 60<\/p>\n

              b-inaktif ise (yapt\u0131\u011f\u0131 fonksiyon bozuklu\u011funa g\u00f6re de\u011ferlendirilir.)<\/p>\n

              5-)Akci\u011fer ameliyatlar\u0131 (y\u0131ll\u0131k kontrollere g\u00f6re)<\/p>\n

              A-Solunum fonksiyonlar\u0131na g\u00f6re<\/p>\n

              a- Az etkilenme varsa \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              b-Orta derecede etkilenme varsa \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              c-A\u011f\u0131r derecede etkilenme varsa \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

              B-Doku kayb\u0131na g\u00f6re<\/p>\n

              a-1 akci\u011ferin tamamen kayb\u0131\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

              b-1 lobun \u00e7\u0131kar\u0131lmas\u0131 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              c-Birden fazla lob al\u0131nm\u0131\u015f ise solunum fonksiyonlar\u0131ndaki azalmaya<\/p>\n

              g\u00f6re de\u011ferlendirilir.<\/p>\n

              13- DAMAR HASTALIKLARI\u00a0\u00a0 <\/strong>\u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

              1-T\u0131kay\u0131c\u0131 damar hastal\u0131\u011f\u0131 olanlarda:<\/p>\n

              A-Arterisklerozis obilterans (ASO):<\/p>\n

              a-Distal arter at\u0131mlar\u0131 palpe edilemiyor,clodicatio intermittant var ve<\/p>\n

              trofik bozukluk yok ise :<\/p>\n

              1-T\u0131bbi tedavinden istifade ediyor ise \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              2-T\u0131bbi tedavinden istifade edemiyor ise \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

              b-Distal arter at\u0131mlar\u0131 palpe edilemiyor,clodicatio intermittant ve<\/p>\n

              trofik bozukluk var ise:<\/p>\n

              1-Cerrahi tedavinden istifade etmi\u015f olanlar \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

              2-Cerrahi tedavinden istifade edememi\u015f olanlar \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

              B-Tromboan gitis obiltrenas (Buerger):<\/p>\n

              a-Sempatektomi ameliyat\u0131 yap\u0131lmam\u0131\u015f ve t\u0131bbi tedavinden yararlan\u0131yorsa\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

              b-Sempatektomi yap\u0131lm\u0131\u015f, trofik bozukluk yok ama clodicatio<\/p>\n

              intermittant varsa\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              c-Sempatektomi yap\u0131lm\u0131\u015f, trofik bozuklu\u011fu ve iskemiye ba\u011fl\u0131<\/p>\n

              istirahat a\u011fr\u0131s\u0131 olanlar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50<\/p>\n

              d-Yukar\u0131daki maddelere ilaveten amputasyon uygulananlara<\/p>\n

              amputasyonla ilgili oranlar Balthzarard ile eklenir.<\/p>\n

              2-Fonksiyonel damar hastal\u0131\u011f\u0131 olanlar (Reynaud Fenomeni, Acrosiyanosoz vs.)<\/p>\n

              a-Trofik bozuklu\u011fu olmayanlar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              b-Trofik bozuklu\u011fu olanlar( doku nerkozu)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              3-Travmatik damar hastal\u0131\u011f\u0131 olanlar<\/p>\n

              a-Cerrahi m\u00fchadele g\u00f6rm\u00fc\u015f, dola\u015f\u0131m bozuklu\u011fu olmayanlar \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a00<\/p>\n

              b-Cerrahi m\u00fchadele g\u00f6rm\u00fc\u015f dola\u015f\u0131m bozuklu\u011fu ve iskemi<\/p>\n

              bulgular\u0131 olanlar \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

              c-Cerrahi m\u00fch\u00fcdele uygulanmas\u0131na ra\u011fmen amputasyon uygulanan<\/p>\n

              vakalar uzuv kayb\u0131 ile ilgili maddelere g\u00f6re de\u011ferlendilir.<\/p>\n

              4-Ven\u00f6z sistem hastal\u0131klar\u0131: Kronik ven\u00f6z yetmezlik ve derin trombozuna<\/p>\n

              ba\u011fl\u0131 ven\u00f6z d\u00f6n\u00fc\u015f bozuklu\u011fu olanlar<\/p>\n

              a-Staz \u00fclseri bulunmayanlar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              b-Staz \u00fclseri bulunanlar<\/p>\n

              1-Tek ekstremite \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              2-\u0130ki ekstremite \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 70<\/p>\n

              5-Lenf sistemi hastal\u0131klar\u0131: (ister Konjentinal ister akkiz lenf\u00f6demi olanlar)<\/p>\n

              a-Hafif derecede lenf\u00f6demi olanlar \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10<\/p>\n

              b-Orta derecede lenf\u00f6demi olanlar<\/p>\n

              1-Tek ekstremite \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              2-\u0130ki ekstremite \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 45<\/p>\n

              c-\u0130leri derecede lenf\u00f6demi olanlar (Y\u00fcr\u00fcme ve hareketi engeleyecek<\/p>\n

              \u00f6l\u00e7\u00fcde )\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80<\/p>\n

              \u00a0<\/strong><\/p>\n

              \u00a0<\/strong><\/p>\n

              \u00a0<\/strong><\/p>\n

              \u00a0<\/strong><\/p>\n

              \u00a0<\/strong><\/p>\n

              \u00a0<\/strong><\/p>\n

              14- ONKOLOJ\u0130<\/strong><\/p>\n


              \nT\u00fcm\u00f6rlar\u0131n S\u0131n\u0131flanmas\u0131 <\/strong><\/p>\n

              1-\u0130leri klinik evreli (Evre lll ve lV) malign t\u00fcm\u00f6r\u00fc olan tedaviye cevap vermeyen<\/p>\n

              \u00e7al\u0131\u015fmayacak durumdaki hastalar\u0131n V\u00fccut \u0130\u015fg\u00fcc\u00fcnden %80’den fazla kaybettikleri kabul edilir.<\/p>\n

              ll-\u00c7al\u0131\u015fabilir ko\u015fulu ile :<\/p>\n

              A-Benign T\u00fcm\u00f6r\u00fc olan hastalar : Primer t\u00fcm\u00f6r\u00fcn sebep oldu\u011fu veya bu t\u00fcm\u00f6re y\u00f6nelik tedavi sonras\u0131nda geli\u015fen doku veya fonksiyon kay\u0131plar\u0131nda \u00c7al\u0131\u015fma g\u00fcc\u00fc kay\u0131p oran\u0131 genel h\u00fck\u00fcmler b\u00f6l\u00fcm\u00fcnde belirtilen miktarlar olup benign t\u00fcm\u00f6r\u00fcnden dolay\u0131 ilave \u00c7al\u0131\u015fma g\u00fcc\u00fc kay\u0131b\u0131 s\u00f6z konusu de\u011fildir.<\/p>\n

              B-Malign transformasyon g\u00f6steren benign t\u00fcm\u00f6rleri : Primer t\u00fcm\u00f6r\u00fcn sebep oldu\u011fu veya bu t\u00fcm\u00f6re y\u00f6nelik tedavi sonras\u0131nda geli\u015fen doku veya fonksiyon kay\u0131plar\u0131nda \u00c7al\u0131\u015fma g\u00fcc\u00fc kay\u0131p oran\u0131 genel h\u00fck\u00fcmler b\u00f6l\u00fcm\u00fcnde belirtilen miktarlara net %5 ilavesi kadard\u0131r.Ancak bu gruptak\u0131 hastalar 6 ayda bir yeniden de\u011ferlendirilerek malign transformasyon g\u00f6sterenler veya progresyon g\u00f6sterecek fonksiyon kayb\u0131 de\u011fi\u015fenler belirlenmelidir.<\/p>\n

              C-\u00c7al\u0131\u015fabilir durumda ve tedaviye cevap veren klinik evreli (Evre l ve ll) malign t\u00fcm\u00f6r\u00fc olan hastalar: Primer t\u00fcm\u00f6r\u00fcn sebep oldu\u011fu veya bu t\u00fcm\u00f6re y\u00f6nelik tedavi sonras\u0131nda geli\u015fen doku veya fonksiyon kay\u0131plar\u0131nda \u00c7al\u0131\u015fma g\u00fcc\u00fc kay\u0131p oran\u0131 genel h\u00fck\u00fcmler b\u00f6l\u00fcm\u00fcnde belirtilen miktarlara net %10 ilavesi kadard\u0131r.Ancak bu gruptaki hastalar 6 ayda bir yeniden de\u011ferlendirilerek, progresyon g\u00f6stererek klinik evresi ve fonksiyon kayb\u0131 de\u011fi\u015fenler belirlenmelidir.<\/p>\n

              15- YANIKLAR\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong>\u00f6z\u00fcr durumuna g\u00f6re \u00e7al\u0131\u015fma g\u00fcc\u00fc kayb\u0131 oran\u0131 %<\/p>\n

              1-DERMA \u0130LE \u0130LG\u0130L\u0130 YANIK ARIZALARI :<\/u><\/p>\n

              \u00a0<\/u><\/p>\n

              a-)V\u00fccut y\u00fczeyinin %10′ unu kaplayan ve ameliyatla giderilmeyen<\/p>\n

              keloid hipertofi\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20<\/p>\n

              b-)V\u00fccut y\u00fczeyini %50′ sini kaplayanlar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30<\/p>\n

              c-)V\u00fccut y\u00fczeyini % 50’sinden fazlas\u0131n\u0131 kaplayanlar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40<\/p>\n

              d-)Sa\u00e7l\u0131 derinin yar\u0131ndan \u00e7ok alan\u0131n\u0131 kaplayan yan\u0131klar ve yaralar\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25<\/p>\n

              e-)Yan\u0131k zeminde geli\u015fen Marjolin \u00fclseri ve skiam\u00f6z kanserler ilgili bran\u015flar taraf\u0131ndan<\/p>\n

              de\u011ferlendilir.<\/p>\n

              ll-AKC\u0130GER VE DAMAR S\u0130STEM\u0130N\u0130 \u0130LG\u0130LEND\u0130REN YANIK ARIZLARI <\/u><\/p>\n

              \u00a0<\/u><\/p>\n

              a-)A\u011f\u0131r inhalasyon travmas\u0131 sonucu Akcigerde kalan sekeler ile ilgili bran\u015f taraf\u0131ndan<\/p>\n

              de\u011ferlendirilir.<\/p>\n

              b-)Akut Trakeotomy sonucu Trekea’da kalan sekeller ilgili bran\u015f taraf\u0131ndan<\/p>\n

              de\u011ferlendilir.<\/p>\n

              c-)Yan\u0131k sonras\u0131 olu\u015fan kal\u0131c\u0131 damar i\u00e7i p\u0131ht\u0131la\u015fmalar\u0131 ilgili bran\u015f taraf\u0131ndan<\/p>\n

              de\u011ferlendilir.<\/p>\n

              d-)Yan\u0131k sonras\u0131 olu\u015fan kal\u0131c\u0131 lenf\u00f6demler ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              lll-KULAK-BURUN S\u0130STEM\u0130N\u0130 \u0130LG\u0130LEND\u0130REN YANIK ARIZALARI<\/u><\/p>\n

              a-)Buruna ait sekeller ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              b-)Kula\u011fa ait kay\u0131p ve sekeller ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              lV-G\u00d6Z \u0130LE \u0130LG\u0130L\u0130 YANIK ARIZALARI<\/u><\/p>\n

              a-)Elektirik yan\u0131klar\u0131 sonras\u0131 olu\u015fan katarakt ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              b-)Termal travma sonucu olu\u015fan Blefaritler ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              V-\u00dcROGENT\u0130AL S\u0130STEM\u0130 \u0130LG\u0130LEND\u0130REN YANIK ARIZALARI<\/u><\/p>\n

              a-) Yan\u0131k komplikasyonu sonucu olu\u015fan \u00dcro-nefropatiler ilgili bran\u015f taraf\u0131ndan<\/p>\n

              de\u011ferlendilir.<\/p>\n

              B-)Elektirik travmas\u0131 ve yan\u0131k sonras\u0131 geli\u015fen gential ve \u00fcriner organ sekelleri ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              Vl-S\u0130ND\u0130R\u0130M S\u0130STEM\u0130N\u0130 \u0130LG\u0130LEND\u0130REN YANIK ARIZALARI<\/u><\/p>\n

              \u00a0<\/u><\/p>\n

              a-)Curling \u00fclseri perforasyonu sonucu opere edilen vakalar ilgili bran\u015f taraf\u0131ndan<\/p>\n

              de\u011ferlendilir.<\/p>\n

              b-)Yan\u0131\u011fa ba\u011fl\u0131 \u00d6zefagus darl\u0131klar\u0131 ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              c-)Yan\u0131k kompiklasyonu sonucu olu\u015fmu\u015f kolessisitisler ilgili bran\u015f taraf\u0131ndan<\/p>\n

              de\u011ferlendilir.<\/p>\n

              d-)Y\u0131ld\u0131r\u0131m \u00e7arpmas\u0131 ve elektirik travmas\u0131 sonucu olu\u015fan a\u011f\u0131r Anorektal harabiyete<\/p>\n

              ba\u011fl\u0131 Kolostomililer ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              E-)Yan\u0131k sonras\u0131 olu\u015fmu\u015f ileri ka\u015feksiler ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              Vll-HAREKET S\u0130STEM\u0130N\u0130 \u0130LG\u0130LEND\u0130REN YANIK ARIZALARI <\/u><\/p>\n

              \u00a0<\/u><\/p>\n

              a-)Yan\u0131k sonras\u0131 uygulanan amp\u00fcstasyon, Dezartik\u00fclasyona ba\u011fl\u0131 extermite kay\u0131plar\u0131 ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              b-)Yan\u0131k sebebiyle kalm\u0131\u015f Sindaktililer ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              c-)Extremiteler ve eklemleri tutan sekel olarak kalm\u0131\u015f kontrakt\u00fcrleri ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              d-)Yan\u0131k sonras\u0131 kostal kondritis ve heterotopik periartik\u00fcler kemik olu\u015fmas\u0131 ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              Vlll-S\u0130N\u0130R S\u0130STEM\u0130N\u0130 \u0130LG\u0130LEND\u0130REN YANIK ARIZALARI<\/u><\/p>\n

              \u00a0<\/u><\/p>\n

              a-)Yan\u0131k sonras\u0131 olu\u015fan merkezi ve periferik sinir lezyonlar\u0131 ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n

              b-)Yan\u0131k sonras\u0131 geli\u015fen kal\u0131c\u0131 ruhsal tepkiler ilgili bran\u015f taraf\u0131ndan de\u011ferlendilir.<\/p>\n","protected":false},"excerpt":{"rendered":"

              Sevgili okuyucular\u0131m\u0131z. Sizlere erken emekli olmak i\u00e7in \u00f6z\u00fcrl\u00fc oran\u0131 hesaplama, erken emeklilik i\u00e7in engllilik oran\u0131\u00a0 hesab\u0131, erken emekli olmak i\u00e7in \u00d6z\u00fcrl\u00fcl\u00fck Engellilik Oran\u0131 Cetvelini sunuyorum.\u00a0 Nedeni \u0130se; Bir arkada\u015f\u0131m erken emekli olmak\u00a0 i\u00e7in hastal\u0131\u011f\u0131n\u0131n engellilik \u00f6z\u00fcrl\u00fcl\u00fck oran\u0131n\u0131n % ka\u00e7 oldu\u011funu merak ettik. Ara\u015ft\u0131rd\u0131k do\u011fru d\u00fcr\u00fcst bir bilgi bulamad\u0131k. Resimde \u00c7al\u0131\u015fma g\u00fcc\u00fc kay\u0131p oranlar\u0131 verilmi\u015ftir. Bildi\u011finiz […]<\/p>\n","protected":false},"author":3,"featured_media":30650,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/posts\/3422"}],"collection":[{"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/comments?post=3422"}],"version-history":[{"count":0,"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/posts\/3422\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/media\/30650"}],"wp:attachment":[{"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/media?parent=3422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/categories?post=3422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stil-vagonu.com\/kadin\/wp-json\/wp\/v2\/tags?post=3422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}